

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/21004> holds various files of this Leiden University dissertation.

Author: Burgel, Nathalie Daniëlle van

Title: Host-pathogen interactions in Lyme disease and their application in diagnostics

Issue Date: 2013-05-29

References

-
- 1 Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease—a tick-borne spirochetosis? *Science* 1982; **216**: 1317-9.
 - 2 Summerton N. Lyme disease in the eighteenth century. *BMJ* 1995; **311**: 1478.
 - 3 Buchwald A. Ein Fall von diffuser idiopathischer Haut-Atrophie. *Arch Dermatol Syph* 1883; **10**: 553-6.
 - 4 Nikulin N. Verhandlungen der Dermatologischen und Venerologischen Gesellschaft zu Moskau. *Dermatol Z* 1896; **3**: 374-5.
 - 5 Afzelius A. Verhandlungen der Dermatologischen Gesellschaft zu Stockholm. *Archives of Dermatology and Syphilis* 1910; **101**: 101-2.
 - 6 Burckhardt JL. Zur Frage der Follikel- und Keimzentrenbildung in der Haut. *Frankfurter Zeitschrift für Pathologie* 1911; **6**: 352-9.
 - 7 Garin C., Bujadoux A. Paralysie par les tiques. *J Med Lyon* 1922: 756-7.
 - 8 Hellerström S. Erythema chronicum migrans Afzelii. *Archiv Dermatologie und Venereologie (Stockholm)* 1930; **11**: 315-21.
 - 9 Bannwarth A. Chronische lymphocytäre meningitis; entzündliche polyneuritis und 'rheumatismus'. *Arch Psychiatr Nervenkr* 1941: 284-376.
 - 10 Thyresson N. Case of dermatitis atrophicans progressiva with subcutaneous and cutaneous tumour-like infiltration, successfully treated with penicillin. *Acta Derm Venereol* 1949; **29**: 302-10.
 - 11 Thyresson N. The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer). *Acta Derm Venereol* 1949; **29**: 572-621.
 - 12 Götz H. [Acrodermatitis chronica atrophicans Herxheimer as an infectious disease.]. *Hautarzt* 1954; **5**: 491-504.
 - 13 Paschoud JM. [Lymphocytoma as a communicable skin disease.]. *Dermatologica* 1957; **114**: 169-71.
 - 14 Scrimenti RJ. Erythema chronicum migrans. *Arch Dermatol* 1970; **102**: 104-5.
 - 15 Steere AC, Malawista SE, Snyderman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. *Arthritis Rheum* 1977; **20**: 7-17.
 - 16 Steere AC, Batsford WP, Weinberg M, et al. Lyme carditis: cardiac abnormalities of Lyme disease. *Ann Intern Med* 1980; **93**: 8-16.
 - 17 Steere AC, Malawista SE, Newman JH, et al. Antibiotic therapy in Lyme disease. *Ann Intern Med* 1980; **93**: 1-8.
 - 18 Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. *Ann Intern Med* 1983; **99**: 767-72.
 - 19 Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. *Ann Intern Med* 1983; **99**: 22-6.
 - 20 Burgdorfer W, Barbour AG, Hayes SF, et al. Erythema chronicum migrans—a tickborne spirochetosis. *Acta Trop* 1983; **40**: 79-83.
 - 21 Steere AC, Grodzicki RL, Kornblatt AN, et al. The spirochetal etiology of Lyme disease. *N Engl J Med* 1983; **308**: 733-40.
 - 22 Benach JL, Bosler EM, Hanrahan JP, et al. Spirochetes isolated from the blood of two patients with Lyme disease. *N Engl J Med* 1983; **308**: 740-2.
 - 23 Barbour AG, Burgdorfer W, Hayes SF, et al. Isolation of A Cultivable Spirochete from Ixodes-Ricinus Ticks of Switzerland. *Current Microbiology* 1983; **8**: 123-6.
 - 24 Saito K, Ito T, Asashima N, et al. Case report: Borrelia valaisiana infection in a Japanese man associated with traveling to foreign countries. *Am J Trop Med Hyg* 2007; **77**: 1124-7.
 - 25 NCBI taxonomy database.
<http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=138&lvl=3&lin=f&kep=1&srchmode=1&unlock>.
 - 26 NCBI. NCBI taxonomy database.
<http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=138&lvl=3&lin=f&kep=1&srchmode=1&unlock>.
 - 27 Barbour AG, Garon CF. Linear plasmids of the bacterium Borrelia burgdorferi have covalently closed ends. *Science* 1987; **237**: 409-11.
 - 28 Schutzer SE, Fraser-Liggett CM, Casjens SR, et al. Whole Genome Sequences of Thirteen Isolates of Borrelia burgdorferi. *J Bacteriol* 2010.
 - 29 Barbour AG. Plasmid analysis of Borrelia burgdorferi, the Lyme disease agent. *J Clin Microbiol* 1988; **26**: 475-8.

- 30 Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, *Borrelia burgdorferi*. *Nature* 1997; **390**: 580-6.
- 31 Hinnebusch J, Barbour AG. Linear- and circular-plasmid copy numbers in *Borrelia burgdorferi*. *J Bacteriol* 1992; **174**: 5251-7.
- 32 Barbour AG, Garon CF. The genes encoding major surface proteins of *Borrelia burgdorferi* are located on a plasmid. *Ann NY Acad Sci* 1988; **539**: 144-53.
- 33 Eggers CH, Casjens S, Hayes SF, et al. Bacteriophages of spirochetes. *J Mol Microbiol Biotechnol* 2000; **2**: 365-73.
- 34 Piesman J. Transmission of Lyme disease spirochetes (*Borrelia burgdorferi*). *Exp Appl Acarol* 1989; **7**: 71-80.
- 35 Kurtenbach K, Hanincova K, Tsao JI, et al. Fundamental processes in the evolutionary ecology of Lyme borreliosis. *Nat Rev Microbiol* 2006; **4**: 660-9.
- 36 Tsao JI. Reviewing molecular adaptations of Lyme borreliosis spirochetes in the context of reproductive fitness in natural transmission cycles. *Vet Res* 2009; **40**: 36.
- 37 Schoeler GB, Lane RS. Efficiency of transovarial transmission of the Lyme disease spirochete, *Borrelia burgdorferi*, in the western blacklegged tick, *Ixodes pacificus* (Acari: Ixodidae). *J Med Entomol* 1993; **30**: 80-6.
- 38 Pal U, Li X, Wang T, et al. TROSPA, an *Ixodes scapularis* receptor for *Borrelia burgdorferi*. *Cell* 2004; **119**: 457-68.
- 39 Pal U, de Silva AM, Montgomery RR, et al. Attachment of *Borrelia burgdorferi* within *Ixodes scapularis* mediated by outer surface protein A. *J Clin Invest* 2000; **106**: 561-9.
- 40 Fikrig E, Pal U, Chen M, et al. OspB antibody prevents *Borrelia burgdorferi* colonization of *Ixodes scapularis*. *Infect Immun* 2004; **72**: 1755-9.
- 41 Benach JL, Coleman JL, Skinner RA, et al. Adult *Ixodes dammini* on rabbits: a hypothesis for the development and transmission of *Borrelia burgdorferi*. *J Infect Dis* 1987; **155**: 1300-6.
- 42 Fingerle V, Laux H, Munderloh UG, et al. Differential expression of outer surface proteins A and C by individual *Borrelia burgdorferi* in different genospecies. *Med Microbiol Immunol* 2000; **189**: 59-66.
- 43 Ribeiro JM, Mather TN, Piesman J, et al. Dissemination and salivary delivery of Lyme disease spirochetes in vector ticks (Acari: Ixodidae). *J Med Entomol* 1987; **24**: 201-5.
- 44 Wikel SK. Tick modulation of host immunity: an important factor in pathogen transmission. *Int J Parasitol* 1999; **29**: 851-9.
- 45 Anguita J, Ramamoorthi N, Hovius JW, et al. Salp15, an *Ixodes scapularis* salivary protein, inhibits CD4(+) T cell activation. *Immunity* 2002; **16**: 849-59.
- 46 Ramamoorthi N, Narasimhan S, Pal U, et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. *Nature* 2005; **436**: 573-7.
- 47 Hovius JW, de Jong MA, den DJ, et al. Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. *PLoS Pathog* 2008; **4**: e31.
- 48 Hovius JW, Schuijt TJ, de Groot KA, et al. Preferential protection of *Borrelia burgdorferi* sensu stricto by a Salp15 homologue in *Ixodes ricinus* saliva. *J Infect Dis* 2008; **198**: 1189-97.
- 49 Guo BP, Norris SJ, Rosenberg LC, et al. Adherence of *Borrelia burgdorferi* to the proteoglycan decorin. *Infect Immun* 1995; **63**: 3467-72.
- 50 Seshu J, Esteve-Gassent MD, Labandeira-Rey M, et al. Inactivation of the fibronectin-binding adhesin gene *bbk32* significantly attenuates the infectivity potential of *Borrelia burgdorferi*. *Mol Microbiol* 2006; **59**: 1591-601.
- 51 Verma A, Brissette CA, Bowman A, et al. *Borrelia burgdorferi* BmpA is a laminin-binding protein. *Infect Immun* 2009; **77**: 4940-6.
- 52 Brissette CA, Bykowski T, Cooley AE, et al. *Borrelia burgdorferi* RevA antigen binds host fibronectin. *Infect Immun* 2009; **77**: 2802-12.
- 53 Brissette CA, Verma A, Bowman A, et al. The *Borrelia burgdorferi* outer-surface protein ErpX binds mammalian laminin. *Microbiology* 2009; **155**: 863-72.
- 54 Zhang JR, Norris SJ. Kinetics and *in vivo* induction of genetic variation of *vlsE* in *Borrelia burgdorferi*. *Infect Immun* 1998; **66**: 3689-97.
- 55 Liang FT, Yan J, Mbow ML, et al. *Borrelia burgdorferi* changes its surface antigenic expression in response to host immune responses. *Infect Immun* 2004; **72**: 5759-67.

-
- 56 Zhang JR, Norris SJ. Genetic variation of the *Borrelia burgdorferi* gene vlsE involves cassette-specific, segmental gene conversion. *Infect Immun* 1998; **66**: 3698-704.
 - 57 Zhang JR, Hardham JM, Barbour AG, et al. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. *Cell* 1997; **89**: 275-85.
 - 58 Stevenson B, von Lackum K, Riley SP, et al. Evolving models of Lyme disease spirochete gene regulation. *Wien Klin Wochenschr* 2006; **118**: 643-52.
 - 59 Kenedy MR, Lenhart TR, Akins DR. The role of *Borrelia burgdorferi* outer surface proteins. *FEMS Immunol Med Microbiol* 2012; **66**: 1-19.
 - 60 Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. *Nat Rev Immunol* 2009; **9**: 729-40.
 - 61 Breitner-Ruddock S, Wurzner R, Schulze J, et al. Heterogeneity in the complement-dependent bacteriolysis within the species of *Borrelia burgdorferi*. *Med Microbiol Immunol (Berl)* 1997; **185**: 253-60.
 - 62 Hovis KM, Tran E, Sundry CM, et al. Selective binding of *Borrelia burgdorferi* OspE paralogs to factor H and serum proteins from diverse animals: possible expansion of the role of OspE in Lyme disease pathogenesis. *Infect Immun* 2006; **74**: 1967-72.
 - 63 Rogers EA, Marconi RT. Delineation of species-specific binding properties of the CspZ protein (BBHo6) of Lyme disease spirochetes: evidence for new contributions to the pathogenesis of *Borrelia* spp. *Infect Immun* 2007; **75**: 5272-81.
 - 64 van Dam AP, Oei A, Jaspars R, et al. Complement-mediated serum sensitivity among spirochetes that cause Lyme disease. *Infect Immun* 1997; **65**: 1228-36.
 - 65 Kurtenbach K, Sewell HS, Ogden NH, et al. Serum complement sensitivity as a key factor in Lyme disease ecology. *Infect Immun* 1998; **66**: 1248-51.
 - 66 Alitalo A, Meri T, Ramo L, et al. Complement evasion by *Borrelia burgdorferi*: serum-resistant strains promote C3b inactivation. *Infect Immun* 2001; **69**: 3685-91.
 - 67 Hellwage J, Meri T, Heikkilä T, et al. The complement regulator factor H binds to the surface protein OspE of *Borrelia burgdorferi*. *J Biol Chem* 2001; **276**: 8427-35.
 - 68 Kraiczy P, Skerka C, Kirschfink M, et al. Mechanism of complement resistance of pathogenic *Borrelia burgdorferi* isolates. *Int Immunopharmacol* 2001; **1**: 393-401.
 - 69 Zipfel PF, Skerka C. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. *Immunol Today* 1999; **20**: 135-40.
 - 70 Zipfel PF, Skerka C, Hellwage J, et al. Factor H family proteins: on complement, microbes and human diseases. *Biochem Soc Trans* 2002; **30**: 971-8.
 - 71 Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. *J Exp Med* 1977; **146**: 257-70.
 - 72 Kuhn S, Skerka C, Zipfel PF. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. *J Immunol* 1995; **155**: 5663-70.
 - 73 Kuhn S, Zipfel PF. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. *Eur J Immunol* 1996; **26**: 2383-7.
 - 74 Kraiczy P, Skerka C, Brade V, et al. Further characterization of complement regulator-acquiring surface proteins of *Borrelia burgdorferi*. *Infect Immun* 2001; **69**: 7800-9.
 - 75 Kraiczy P, Hellwage J, Skerka C, et al. Complement resistance of *Borrelia burgdorferi* correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. *J Biol Chem* 2004; **279**: 2421-9.
 - 76 Kraiczy P, Rossmann E, Brade V, et al. Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of *Borrelia burgdorferi*. *Wiener Klinische Wochenschrift* 2006; **118**: 669-76.
 - 77 Wallich R, Pattathu J, Kitziratschky V, et al. Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes *Borrelia afzelii* and *Borrelia garinii*. *Infect Immun* 2005; **73**: 2351-9.
 - 78 Hallstrom T, Haupt K, Kraiczy P, et al. Complement regulator-acquiring surface protein 1 of *Borrelia burgdorferi* binds to human bone morphogenic protein 2, several extracellular matrix proteins, and plasminogen. *J Infect Dis* 2010; **202**: 490-8.
 - 79 Bykowski T, Woodman ME, Cooley AE, et al. *Borrelia burgdorferi* complement regulator-acquiring surface proteins (BbCRASPs): Expression patterns during the mammal-tick infection cycle. *Int J Med Microbiol* 2008; **298 Suppl 1**: 249-56.

-
- 80 Bykowski T, Woodman ME, Cooley AE, et al. Coordinated expression of *Borrelia burgdorferi* complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle. *Infect Immun* 2007; **75**: 4227-36.
- 81 Rossmann E, Kitiratschky V, Hofmann H, et al. *Borrelia burgdorferi* complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes is expressed in humans and induces antibody responses restricted to nondenatured structural determinants. *Infect Immun* 2006; **74**: 7024-8.
- 82 Lederer S, Brenner C, Stehle T, et al. Quantitative analysis of *Borrelia burgdorferi* gene expression in naturally (tick) infected mouse strains. *Med Microbiol Immunol* 2005; **194**: 81-90.
- 83 Wallich R, Jahraus O, Stehle T, et al. Artificial-infection protocols allow immunodetection of novel *Borrelia burgdorferi* antigens suitable as vaccine candidates against Lyme disease. *Eur J Immunol* 2003; **33**: 708-19.
- 84 Rogers EA, Abdunnur SV, McDowell JV, et al. Comparative analysis of the properties and ligand binding characteristics of CspZ, a factor H binding protein, derived from *Borrelia burgdorferi* isolates of human origin. *Infect Immun* 2009; **77**: 4396-405.
- 85 Hartmann K, Corvey C, Skerka C, et al. Functional characterization of BbCRASP-2, a distinct outer membrane protein of *Borrelia burgdorferi* that binds host complement regulators factor H and FHL-1. *Mol Microbiol* 2006; **61**: 1220-36.
- 86 Coleman AS, Yang X, Kumar M, et al. *Borrelia burgdorferi* complement regulator-acquiring surface protein 2 does not contribute to complement resistance or host infectivity. *PLoS ONE* 2008; **3**: 3010e.
- 87 Zhang H, Marconi RT. Demonstration of cotranscription and 1-methyl-3-nitroso-nitroguanidine induction of a 30-gene operon of *Borrelia burgdorferi*: evidence that the 32-kilobase circular plasmids are prophages. *J Bacteriol* 2005; **187**: 7985-95.
- 88 Hammerschmidt C, Hallstrom T, Skerka C, et al. Contribution of the infection-associated complement regulator-acquiring surface protein 4 (ErpC) to complement resistance of *Borrelia burgdorferi*. *Clin Dev Immunol* 2012; **2012**: 349657.
- 89 Haupt K, Kraiczy P, Wallich R, et al. Binding of human factor H-related protein 1 to serum-resistant *Borrelia burgdorferi* is mediated by borrelial complement regulator-acquiring surface proteins. *J Infect Dis* 2007; **196**: 124-33.
- 90 Siegel C, Hallstrom T, Skerka C, et al. Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of *Borrelia burgdorferi*. *PLoS ONE* 2010; **5**: e13519.
- 91 Kenedy MR, Akins DR. The OspE-related proteins inhibit complement deposition and enhance serum resistance of *Borrelia burgdorferi*, the Lyme disease spirochete. *Infect Immun* 2011; **79**: 1451-7.
- 92 Miller JC, Stevenson B. *Borrelia burgdorferi* erp genes are expressed at different levels within tissues of chronically infected mammalian hosts. *Int J Med Microbiol* 2006; **296**: 185-94.
- 93 Miller JC, Narayan K, Stevenson B, et al. Expression of *Borrelia burgdorferi* erp genes during infection of non-human primates. *Microb Pathog* 2005.
- 94 Miller JC, Narayan K, Stevenson B, et al. Expression of *Borrelia burgdorferi* erp genes during infection of non-human primates. *Microb Pathog* 2005; **39**: 27-33.
- 95 Miller JC, Stevenson B. Increased expression of *Borrelia burgdorferi* factor H-binding surface proteins during transmission from ticks to mice. *Int J Med Microbiol* 2004; **293 Suppl 37**: 120-5.
- 96 Miller JC, von Lackum K, Babb K, et al. Temporal analysis of *Borrelia burgdorferi* Erp protein expression throughout the mammal-tick infectious cycle. *Infect Immun* 2003; **71**: 6943-52.
- 97 Metts MS, McDowell JV, Theisen M, et al. Analysis of the OspE determinants involved in binding of factor H and OspE-targeting antibodies elicited during *Borrelia burgdorferi* infection in mice. *Infect Immun* 2003; **71**: 3587-96.
- 98 Woodman ME, Cooley AE, Miller JC, et al. *Borrelia burgdorferi* binding of host complement regulator factor H is not required for efficient mammalian infection. *Infect Immun* 2007; **75**: 3131-9.
- 99 Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. *Nat Genet* 2002; **31**: 424-8.
- 100 Schuijt TJ, Hovius JW, van Burgel ND, et al. The tick salivary protein Salp15 inhibits the killing of serum-sensitive *Borrelia burgdorferi* sensu lato isolates. *Infect Immun* 2008; **76**: 2888-94.

-
- 101 Schuijt TJ, Coumou J, Narasimhan S, et al. A tick mannose-binding lectin inhibitor interferes with the vertebrate complement cascade to enhance transmission of the Lyme disease agent. *Cell Host Microbe* 2011; **10**: 136-46.
- 102 Kern A, Collin E, Barthel C, et al. Tick Saliva Represses Innate Immunity and Cutaneous Inflammation in a Murine Model of Lyme Disease. *Vector Borne Zoonotic Dis* 2011.
- 103 Pausa M, Pellis V, Cinco M, et al. Serum-resistant strains of *Borrelia burgdorferi* evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. *J Immunol* 2003; **170**: 3214-22.
- 104 Assous MV, Postic D, Paul G, et al. Western blot analysis of sera from Lyme borreliosis patients according to the genomic species of the *Borrelia* strains used as antigens. *Eur J Clin Microbiol Infect Dis* 1993; **12**: 261-8.
- 105 van Dam AP, Kuiper H, Vos K, et al. Different genospecies of *Borrelia burgdorferi* are associated with distinct clinical manifestations of Lyme borreliosis. *Clin Infect Dis* 1993; **17**: 708-17.
- 106 Balmelli T, Piffaretti JC. Association between different clinical manifestations of Lyme disease and different species of *Borrelia burgdorferi* sensu lato. *Res Microbiol* 1995; **146**: 329-40.
- 107 Brouqui P, Bacellar F, Baranton G, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. *Clin Microbiol Infect* 2004; **10**: 1108-32.
- 108 CDC guideline. CDC Lyme disease case definitions. In: 2011
- 109 EUCALB. EUCALB guideline. In: 2009
- 110 Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. *Clin Microbiol Infect* 2011; **17**: 69-79.
- 111 Oschmann P, Dorndorf W, Hornig C, et al. Stages and syndromes of neuroborreliosis. *J Neurol* 1998; **245**: 262-72.
- 112 Dhôte R., Basse-Guerineau AL, Beaumesnil V, et al. Full spectrum of clinical, serological, and epidemiological features of complicated forms of Lyme borreliosis in the Paris, France, area. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 809-15.
- 113 Peltomaa M, Pyykko I, Seppala I, et al. Lyme borreliosis and facial paralysis—a prospective analysis of risk factors and outcome. *Am J Otolaryngol* 2002; **23**: 125-32.
- 114 Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with *Borrelia burgdorferi* specific intrathecal antibody production. *Brain* 1992; **115 (Pt 2)**: 399-423.
- 115 Fulop B, Poggensee G. Epidemiological situation of Lyme borreliosis in Germany: surveillance data from six Eastern German States, 2002 to 2006. *Parasitol Res* 2008; **103 Suppl 1**: S117-S120.
- 116 Huppertz HI, Bohme M, Standaert SM, et al. Incidence of Lyme borreliosis in the Wurzburg region of Germany. *Eur J Clin Microbiol Infect Dis* 1999; **18**: 697-703.
- 117 Berglund J, Eitrem R, Ornstein K, et al. An epidemiologic study of Lyme disease in southern Sweden. *N Engl J Med* 1995; **333**: 1319-27.
- 118 Vanousova D, Hercogova J. Lyme borreliosis treatment. *Dermatol Ther* 2008; **21**: 101-9.
- 119 Hofhuis A, van der Giessen JW, Borgsteede FH, et al. Lyme borreliosis in the Netherlands: strong increase in GP consultations and hospital admissions in past 10 years. *Euro Surveill* 2006; **11**: Eo60622.
- 120 Smith R, O'Connell S, Palmer S. Lyme disease surveillance in England and Wales, 1986-1998. *Emerg Infect Dis* 2000; **6**: 404-7.
- 121 Asbrink E, Hovmark A. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). *Ann N Y Acad Sci* 1988; **539**: 4-15.
- 122 Asbrink E, Olsson I, Hovmark A. Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients. *Zentralbl Bakteriol Mikrobiol Hyg A* 1986; **263**: 229-36.
- 123 Strle F, Nelson JA, Ruzic-Sabljic E, et al. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. *Clin Infect Dis* 1996; **23**: 61-5.
- 124 Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. *Ann Intern Med* 2002; **136**: 421-8.
- 125 Mullegger RR. Dermatological manifestations of Lyme borreliosis. *Eur J Dermatol* 2004; **14**: 296-309.
- 126 Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. *Ann Intern Med* 1983; **99**: 76-82.

-
- 127 Asbrink E, Olsson I. Clinical manifestations of erythema chronicum migrans Afzelius in 161 patients. A comparison with Lyme disease. *Acta Derm Venereol* 1985; **65**: 43-52.
- 128 Steere AC, Sikand VK, Schoen RT, et al. Asymptomatic infection with *Borrelia burgdorferi*. *Clin Infect Dis* 2003; **37**: 528-32.
- 129 Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. *Am J Med* 1996; **100**: 502-8.
- 130 Wormser GP, Liveris D, Nowakowski J, et al. Association of specific subtypes of *Borrelia burgdorferi* with hematogenous dissemination in early Lyme disease. *J Infect Dis* 1999; **180**: 720-5.
- 131 Carlsson SA, Granlund H, Jansson C, et al. Characteristics of erythema migrans in *Borrelia afzelii* and *Borrelia garinii* infections. *Scand J Infect Dis* 2003; **35**: 31-3.
- 132 Steere AC, Dhar A, Hernandez J, et al. Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. *Am J Med* 2003; **114**: 58-62.
- 133 Maraspin V, Cimperman J, Lotric-Furlan S, et al. Solitary borrelial lymphocytoma in adult patients. *Wien Klin Wochenschr* 2002; **114**: 515-23.
- 134 Picken RN, Strle F, Ruzic-Sabljić E, et al. Molecular subtyping of *Borrelia burgdorferi* sensu lato isolates from five patients with solitary lymphocytoma. *J Invest Dermatol* 1997; **108**: 92-7.
- 135 Lenormand C, Jaulhac B, De MS, et al. Species of *Borrelia burgdorferi* complex that cause borrelial lymphocytoma in France. *Br J Dermatol* 2009; **161**: 174-6.
- 136 Asbrink E. Cutaneous manifestations of Lyme borreliosis. Clinical definitions and differential diagnoses. *Scand J Infect Dis Suppl* 1991; **77**: 44-50.
- 137 Smetanick MT, Zellis SL, Ermolovich T. Acrodermatitis chronica atrophicans: a case report and review of the literature. *Cutis* 2010; **85**: 247-52.
- 138 DiCaudo DJ, Su WP, Marshall WF, et al. Acrodermatitis chronica atrophicans in the United States: clinical and histopathologic features of six cases. *Cutis* 1994; **54**: 81-4.
- 139 Andres C, Ziai M, Bruckbauer H, et al. Acrodermatitis chronica atrophicans in two children. *Int J Dermatol* 2010; **49**: 180-3.
- 140 Zalaudek I, Leinweber B, Kerl H, et al. Acrodermatitis chronica atrophicans in a 15-year-old girl misdiagnosed as venous insufficiency for 6 years. *J Am Acad Dermatol* 2005; **52**: 1091-4.
- 141 Picken RN, Strle F, Picken MM, et al. Identification of three species of *Borrelia burgdorferi* sensu lato (*B. burgdorferi* sensu stricto, *B. garinii*, and *B. afzelii*) among isolates from acrodermatitis chronica atrophicans lesions. *J Invest Dermatol* 1998; **110**: 211-4.
- 142 Busch U, Hizo-Teufel C, Bohmer R, et al. *Borrelia burgdorferi* sensu lato strains isolated from cutaneous Lyme borreliosis biopsies differentiated by pulsed-field gel electrophoresis. *Scand J Infect Dis* 1996; **28**: 583-9.
- 143 Rijpkema SG, Tazelaar DJ, Molkenboer MJ, et al. Detection of *Borrelia afzelii*, *Borrelia burgdorferi* sensu stricto, *Borrelia garinii* and group VS116 by PCR in skin biopsies of patients with erythema migrans and acrodermatitis chronica atrophicans. *Clin Microbiol Infect* 1997; **3**: 109-16.
- 144 Kristoferitsch W, Sluga E, Graf M, et al. Neuropathy associated with acrodermatitis chronica atrophicans. Clinical and morphological features. *Ann NY Acad Sci* 1988; **539**: 35-45.
- 145 Kindstrand E, Nilsson BY, Hovmark A, et al. Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment. *Acta Neurol Scand* 2002; **106**: 253-7.
- 146 Kindstrand E, Nilsson BY, Hovmark A, et al. Polyneuropathy in late Lyme borreliosis - a clinical, neurophysiological and morphological description. *Acta Neurol Scand* 2000; **101**: 47-52.
- 147 Kindstrand E, Nilsson BY, Hovmark A, et al. Peripheral neuropathy in acrodermatitis chronica atrophicans - a late *Borrelia* manifestation. *Acta Neurol Scand* 1997; **95**: 338-45.
- 148 Marsch WC, Mayet A, Wolter M. Cutaneous fibroses induced by *Borrelia burgdorferi*. *Br J Dermatol* 1993; **128**: 674-8.
- 149 Binder B, Kerl H, Müllegger R. Differenzialdiagnose der Acrodermatitis chronica atrophicans unter besonderer Berücksichtigung der chronisch-venösen Insuffizienz. *Phlebologie* 2004; **33**: 191-8.
- 150 Smith BG, Cruz AI, Jr., Milewski MD, et al. Lyme disease and the orthopaedic implications of lyme arthritis. *J Am Acad Orthop Surg* 2011; **19**: 91-100.
- 151 Priem S, Munkelt K, Franz JK, et al. [Epidemiology and therapy of Lyme arthritis and other manifestations of Lyme borreliosis in Germany: results of a nation-wide survey]. *Z Rheumatol* 2003; **62**: 450-8.
- 152 Christova I, Komitova R. Clinical and epidemiological features of Lyme borreliosis in Bulgaria. *Wien Klin Wochenschr* 2004; **116**: 42-6.

-
- 153 Huppertz HI, Karch H, Suschke HJ, et al. Lyme arthritis in European children and adolescents. The Pediatric Rheumatology Collaborative Group. *Arthritis Rheum* 1995; **38**: 361-8.
 - 154 Saulsbury FT. Lyme arthritis presenting as transient synovitis of the hip. *Clin Pediatr (Phila)* 2008; **47**: 833-5.
 - 155 Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. *Ann Intern Med* 1987; **107**: 725-31.
 - 156 Eichenfield AH, Goldsmith DP, Benach JL, et al. Childhood Lyme arthritis: experience in an endemic area. *J Pediatr* 1986; **109**: 753-8.
 - 157 Lelovas P, Dontas I, Bassiakou E, et al. Cardiac implications of Lyme disease, diagnosis and therapeutic approach. *Int J Cardiol* 2008; **129**: 15-21.
 - 158 van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. *Scand J Infect Dis Suppl* 1991; **77**: 81-4.
 - 159 Halperin JJ, Volkman DJ, Wu P. Central nervous system abnormalities in Lyme neuroborreliosis. *Neurology* 1991; **41**: 1571-82.
 - 160 Nadelman RB, Wormser GP. Lyme borreliosis. *Lancet* 1998; **352**: 557-65.
 - 161 Bigaignon G, Tomasi JP, Goubau P, et al. A clinical and sero-epidemiological study of 190 Belgian patients suffering from Lyme borreliosis. *Acta Clin Belg* 1989; **44**: 174-81.
 - 162 Cimmino M, Granstrom M, Gray JS, et al. European Lyme borreliosis clinical spectrum. *Zentralbl Bakteriol* 1998; **287**: 248-52.
 - 163 Christen HJ, Hanefeld F. Neurologic complications of erythema-migrans-disease in childhood-clinical aspects. *Zentralbl Bakteriol Mikrobiol Hyg A* 1987; **263**: 337-42.
 - 164 Pfister HW, Einhaupl KM, Wilske B, et al. Bannwarth's syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis. *Zentralbl Bakteriol Mikrobiol Hyg A* 1987; **263**: 343-7.
 - 165 Tveitnes D, Oymar K, Natas O. Acute facial nerve palsy in children: how often is it Lyme borreliosis? *Scand J Infect Dis* 2007; **39**: 425-31.
 - 166 Arnez M, Ruzic-Sabljić E. Lyme borreliosis and acute peripheral facial palsy in Slovenian children. *Pediatr Infect Dis J* 2010; **29**: 182-4.
 - 167 Christen HJ, Bartlau N, Hanefeld F, et al. Peripheral facial palsy in childhood--Lyme borreliosis to be suspected unless proven otherwise. *Acta Paediatr Scand* 1990; **79**: 1219-24.
 - 168 Christen HJ. Lyme neuroborreliosis in children. *Ann Med* 1996; **28**: 235-40.
 - 169 Peitersen E. Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. *Acta Otolaryngol Suppl* 2002: 4-30.
 - 170 Peltomaa M, Pyykkö I, Seppala I, et al. Lyme borreliosis--an unusual cause of vertigo. *Auris Nasus Larynx* 1998; **25**: 233-42.
 - 171 Rothermel H, Hedges TR, III, Steere AC. Optic neuropathy in children with Lyme disease. *Pediatrics* 2001; **108**: 477-81.
 - 172 Sibony P, Halperin J, Coyle PK, et al. Reactive Lyme serology in optic neuritis. *J Neuroophthalmol* 2005; **25**: 71-82.
 - 173 Ishizaki H, Pyykkö I, Nozue M. Neuroborreliosis in the etiology of vestibular neuronitis. *Acta Otolaryngol Suppl* 1993; **503**: 67-9.
 - 174 Smith IS, Rechlin DP. Delayed diagnosis of neuroborreliosis presenting as bell palsy and meningitis. *J Am Osteopath Assoc* 2010; **110**: 441-4.
 - 175 Hyden D, Roberg M, Odkvist L. Borreliosis as a cause of sudden deafness and vestibular neuritis in Sweden. *Acta Otolaryngol Suppl* 1995; **520 Pt 2**: 320-2.
 - 176 Kruger H, Kohlhepp W, König S. Follow-up of antibioticly treated and untreated neuroborreliosis. *Acta Neurol Scand* 1990; **82**: 59-67.
 - 177 Pfister HW, Rupperecht TA. Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients. *Int J Med Microbiol* 2006; **296 Suppl 40**: 11-6.
 - 178 Kaiser R. Variable CSF findings in early and late Lyme neuroborreliosis: a follow-up study in 47 patients. *J Neurol* 1994; **242**: 26-36.
 - 179 Pachner AR. Neurologic manifestations of Lyme disease, the new "great imitator". *Rev Infect Dis* 1989; **11 Suppl 6**: S1482-S1486.
 - 180 Huppertz HI, Munchmeier D, Lieb W. Ocular manifestations in children and adolescents with Lyme arthritis. *Br J Ophthalmol* 1999; **83**: 1149-52.
 - 181 Mikkilä HO, Seppala IJ, Viljanen MK, et al. The expanding clinical spectrum of ocular Lyme borreliosis. *Ophthalmology* 2000; **107**: 581-7.

-
- 182 Mora P, Carta A. Ocular manifestations of Lyme borreliosis in Europe. *Int J Med Sci* 2009; **6**: 124-5.
- 183 Zanchi AC, Gingold AR, Theise ND, et al. Necrotizing granulomatous hepatitis as an unusual manifestation of Lyme disease. *Dig Dis Sci* 2007; **52**: 2629-32.
- 184 Reimers CD, Pongratz DE, Neubert U, et al. Myositis caused by *Borrelia burgdorferi*: report of four cases. *J Neurol Sci* 1989; **91**: 215-26.
- 185 Nguyen H, Le C, Nguyen H. Acute Lyme infection presenting with amyopathic dermatomyositis and rapidly fatal interstitial pulmonary fibrosis: a case report. *J Med Case Reports* 2010; **4**: 187.
- 186 Holmgren AR, Matteson EL. Lyme myositis. *Arthritis Rheum* 2006; **54**: 2697-700.
- 187 Muller-Felber W, Reimers CD, de KJ, et al. Myositis in Lyme borreliosis: an immunohistochemical study of seven patients. *J Neurol Sci* 1993; **118**: 207-12.
- 188 van Assen S, Bosma F, Staals LM, et al. Acute disseminated encephalomyelitis associated with *Borrelia burgdorferi*. *J Neurol* 2004; **251**: 626-9.
- 189 Bockenstedt LK, Kang I, Chang C, et al. CD4+ T helper 1 cells facilitate regression of murine Lyme carditis. *Infect Immun* 2001; **69**: 5264-9.
- 190 Belperron AA, Dailey CM, Booth CJ, et al. Marginal zone B-cell depletion impairs murine host defense against *Borrelia burgdorferi* infection. *Infect Immun* 2007; **75**: 3354-60.
- 191 Lawrenz MB, Wooten RM, Zachary JF, et al. Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice. *Infect Immun* 2003; **71**: 4432-40.
- 192 Yrjanainen H, Hytonen J, Song XY, et al. Anti-tumor necrosis factor-alpha treatment activates *Borrelia burgdorferi* spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. *J Infect Dis* 2007; **195**: 1489-96.
- 193 Furst B, Glatz M, Kerl H, et al. The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of *Borrelia* antibodies in 33 patients. *Clin Exp Dermatol* 2006; **31**: 509-14.
- 194 Maraspin V, Cimperman J, Lotric-Furlan S, et al. Erythema migrans in solid-organ transplant recipients. *Clin Infect Dis* 2006; **42**: 1751-4.
- 195 Harrer T, Geissdorfer W, Schoerner C, et al. Seronegative Lyme neuroborreliosis in a patient on treatment for chronic lymphatic leukemia. *Infection* 2007; **35**: 110-3.
- 196 Lakos A, Solymosi N. Maternal Lyme borreliosis and pregnancy outcome. *Int J Infect Dis* 2010; **14**: e494-e498.
- 197 Maraspin V, Cimperman J, Lotric-Furlan S, et al. Erythema migrans in pregnancy. *Wien Klin Wochenschr* 1999; **111**: 933-40.
- 198 Berger BW, Clemmensen OJ, Ackerman AB. Lyme disease is a spirochetosis. A review of the disease and evidence for its cause. *Am J Dermatopathol* 1983; **5**: 111-24.
- 199 Berger BW, Clemmensen OJ, Gottlieb GJ. Spirochetes in lesions of erythema chronicum migrans. *Am J Dermatopathol* 1982; **4**: 555-6.
- 200 Neubert U, Krampitz HE, Engl H. Microbiological findings in erythema (chronicum) migrans and related disorders. *Zentralbl Bakteriol Mikrobiol Hyg A* 1986; **263**: 237-52.
- 201 Marcus LC, Steere AC, Duray PH, et al. Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. *Ann Intern Med* 1985; **103**: 374-6.
- 202 Kornblatt AN, Steere AC, Brownstein DG. Experimental Lyme disease in rabbits: spirochetes found in erythema migrans and blood. *Infect Immun* 1984; **46**: 220-3.
- 203 Klein J, Stanek G, Bittner R, et al. Lyme borreliosis as a cause of myocarditis and heart muscle disease. *Eur Heart J* 1991; **12 Suppl D**: 73-5.
- 204 Johnston YE, Duray PH, Steere AC, et al. Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. *Am J Pathol* 1985; **118**: 26-34.
- 205 Hoffmann JC, Stichtenoeth DO, Zeidler H, et al. Lyme disease in a 74-year-old forest owner with symptoms of dermatomyositis. *Arthritis Rheum* 1995; **38**: 1157-60.
- 206 de KJ, Hoogkamp-Korstanje JA. Diagnosis of Lyme disease by demonstration of spirochetes in tissue biopsies. *Zentralbl Bakteriol Mikrobiol Hyg A* 1986; **263**: 179-88.
- 207 de KJ, Bosma RB, Hoogkamp-Korstanje JA. Demonstration of spirochaetes in patients with Lyme disease with a modified silver stain. *J Med Microbiol* 1987; **23**: 261-7.
- 208 de KJ, Hoogkamp-Korstanje JA, van der Linde MR, et al. Demonstration of spirochetes in cardiac biopsies of patients with Lyme disease. *J Infect Dis* 1989; **160**: 150-3.
- 209 Reimers CD, de KJ, Neubert U, et al. *Borrelia burgdorferi* myositis: report of eight patients. *J Neurol* 1993; **240**: 278-83.

-
- 210 Bergler-Klein J, Sochor H, Stanek G, et al. Indium 111-monoclonal antimyosin antibody and magnetic resonance imaging in the diagnosis of acute Lyme myopericarditis. *Arch Intern Med* 1993; **153**: 2696-700.
- 211 Bartunek P, Gorican K, Mrazek V, et al. Lyme borreliosis infection as a cause of dilated cardiomyopathy. *Prague Med Rep* 2006; **107**: 213-26.
- 212 Valesova M, Trnavsky K, Hulinska D, et al. Detection of *Borrelia* in the synovial tissue from a patient with Lyme borreliosis by electron microscopy. *J Rheumatol* 1989; **16**: 1502-5.
- 213 Dejmekova H, Hulinska D, Tegzova D, et al. Seronegative Lyme arthritis caused by *Borrelia garinii*. *Clin Rheumatol* 2002; **21**: 330-4.
- 214 Dietrich T, Geissdorfer W, Schlotzer-Schrehardt U, et al. *Borrelia*-associated crystalline keratopathy with intracorneal detection of *Borrelia garinii* by electron microscopy and polymerase chain reaction. *Cornea* 2008; **27**: 498-500.
- 215 Stoenner HG, Dodd T, Larsen C. Antigenic variation of *Borrelia hermsii*. *J Exp Med* 1982; **156**: 1297-311.
- 216 Preac-Mursic V, Wilske B, Schierz G. European *Borrelia burgdorferi* isolated from humans and ticks culture conditions and antibiotic susceptibility. *Zentralbl Bakteriol Mikrobiol Hyg A* 1986; **263**: 112-8.
- 217 Pollack RJ, Telford SR, III, Spielman A. Standardization of medium for culturing Lyme disease spirochetes. *J Clin Microbiol* 1993; **31**: 1251-5.
- 218 Nadelman RB, Pavia CS, Magnarelli LA, et al. Isolation of *Borrelia burgdorferi* from the blood of seven patients with Lyme disease. *Am J Med* 1990; **88**: 21-6.
- 219 Steere AC, Grodzicki RL, Craft JE, et al. Recovery of Lyme disease spirochetes from patients. *Yale J Biol Med* 1984; **57**: 557-60.
- 220 Goodman JL, Bradley JF, Ross AE, et al. Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction. *Am J Med* 1995; **99**: 6-12.
- 221 Nadelman RB, Schwartz I, Wormser GP. Detecting *Borrelia burgdorferi* in blood from patients with Lyme disease. *J Infect Dis* 1994; **169**: 1410-1.
- 222 Steere AC, Grodzicki RL, Kornblatt AN, et al. The spirochetal etiology of Lyme disease. *N Engl J Med* 1983; **308**: 733-40.
- 223 Wallach FR, Forni AL, Hariprashad J, et al. Circulating *Borrelia burgdorferi* in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. *J Infect Dis* 1993; **168**: 1541-3.
- 224 Wormser GP, Nowakowski J, Nadelman RB, et al. Improving the yield of blood cultures for patients with early Lyme disease. *J Clin Microbiol* 1998; **36**: 296-8.
- 225 Wormser GP, Bittker S, Cooper D, et al. Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease. *J Clin Microbiol* 2000; **38**: 1648-50.
- 226 Wormser GP, Bittker S, Cooper D, et al. Yield of large-volume blood cultures in patients with early Lyme disease. *J Infect Dis* 2001; **184**: 1070-2.
- 227 Coulter P, Lema C, Flayhart D, et al. Two-year evaluation of *Borrelia burgdorferi* culture and supplemental tests for definitive diagnosis of Lyme disease. *J Clin Microbiol* 2005; **43**: 5080-4.
- 228 Wormser GP. Hematogenous dissemination in early Lyme disease. *Wien Klin Wochenschr* 2006; **118**: 634-7.
- 229 Nowakowski J, McKenna D, Nadelman RB, et al. Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. *Clin Infect Dis* 2009; **49**: 1733-5.
- 230 Schwarzova K, Kost'anova Z, Holeckova K, et al. Direct detection of *Borrelia burgdorferi* spirochetes in patients with early disseminated Lyme borreliosis. *Cent Eur J Public Health* 2009; **17**: 179-82.
- 231 Maraspin V, Ogrinc K, Ruzic-Sabljić E, et al. Isolation of *Borrelia burgdorferi* sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. *Infection* 2010.
- 232 Arnez M, Ruzic-Sabljić E, Ahcan J, et al. Isolation of *Borrelia burgdorferi* sensu lato from blood of children with solitary erythema migrans. *Pediatr Infect Dis J* 2001; **20**: 251-5.
- 233 Maraspin V, Ruzic-Sabljić E, Cimperman J, et al. Isolation of *Borrelia burgdorferi* sensu lato from blood of patients with erythema migrans. *Infection* 2001; **29**: 65-70.
- 234 Steere AC, McHugh G, Damle N, et al. Prospective study of serologic tests for Lyme disease. *Clin Infect Dis* 2008; **47**: 188-95.

-
- 235 Agüero-Rosenfeld ME, Wang G, Schwartz I, et al. Diagnosis of Lyme borreliosis. *Clin Microbiol Rev* 2005; **18**: 484-509.
- 236 Berger BW, Johnson RC, Kodner C, et al. Cultivation of *Borrelia burgdorferi* from erythema migrans lesions and perilesional skin. *J Clin Microbiol* 1992; **30**: 359-61.
- 237 Mitchell PD, Reed KD, Vandermause MF, et al. Isolation of *Borrelia burgdorferi* from skin biopsy specimens of patients with erythema migrans. *Am J Clin Pathol* 1993; **99**: 104-7.
- 238 Jurca T, Ruzic-Sabljić E, Lotric-Furlan S, et al. Comparison of peripheral and central biopsy sites for the isolation of *Borrelia burgdorferi* sensu lato from erythema migrans skin lesions. *Clin Infect Dis* 1998; **27**: 636-8.
- 239 Asbrink E, Hovmark A. Successful cultivation of spirochetes from skin lesions of patients with erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. *Acta Pathol Microbiol Immunol Scand B* 1985; **93**: 161-3.
- 240 Cerar T, Ogrinc K, Cimperman J, et al. Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. *J Clin Microbiol* 2008; **46**: 3375-9.
- 241 Snyderman DR, Schenkein DP, Berardi VP, et al. *Borrelia burgdorferi* in joint fluid in chronic Lyme arthritis. *Ann Intern Med* 1986; **104**: 798-800.
- 242 Schmidli J, Hunziker T, Moesli P, et al. Cultivation of *Borrelia burgdorferi* from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. *J Infect Dis* 1988; **158**: 905-6.
- 243 Hyde FW, Johnson RC, White TJ, et al. Detection of antigens in urine of mice and humans infected with *Borrelia burgdorferi*, etiologic agent of Lyme disease. *J Clin Microbiol* 1989; **27**: 58-61.
- 244 Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. *Am J Med* 2001; **110**: 217-9.
- 245 Coyle PK, Deng Z, Schutzer SE, et al. Detection of *Borrelia burgdorferi* antigens in cerebrospinal fluid. *Neurology* 1993; **43**: 1093-8.
- 246 Coyle PK, Schutzer SE, Deng Z, et al. Detection of *Borrelia burgdorferi*-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. *Neurology* 1995; **45**: 2010-5.
- 247 Dattwyler RJ, Volkman DJ, Luft BJ, et al. Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to *Borrelia burgdorferi*. *N Engl J Med* 1988; **319**: 1441-6.
- 248 Dressler F, Yoshinari NH, Steere AC. The T-cell proliferative assay in the diagnosis of Lyme disease. *Ann Intern Med* 1991; **115**: 533-9.
- 249 Busch DH, Jassoy C, Brinckmann U, et al. Detection of *Borrelia burgdorferi*-specific CD8+ cytotoxic T cells in patients with Lyme arthritis. *J Immunol* 1996; **157**: 3534-41.
- 250 Kalish RS, Wood JA, Golde W, et al. Human T lymphocyte response to *Borrelia burgdorferi* infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. *J Infect Dis* 2003; **187**: 102-8.
- 251 Buechner SA, Lautenschlager S, Itin P, et al. Lymphoproliferative responses to *Borrelia burgdorferi* in patients with erythema migrans, acrodermatitis chronica atrophicans, lymphadenosis benigna cutis, and morphea. *Arch Dermatol* 1995; **131**: 673-7.
- 252 Sigal LH, Steere AC, Freeman DH, et al. Proliferative responses of mononuclear cells in Lyme disease. Reactivity to *Borrelia burgdorferi* antigens is greater in joint fluid than in blood. *Arthritis Rheum* 1986; **29**: 761-9.
- 253 Pachner AR, Steere AC, Sigal LH, et al. Antigen-specific proliferation of CSF lymphocytes in Lyme disease. *Neurology* 1985; **35**: 1642-4.
- 254 Horowitz HW, Pavia CS, Bittker S, et al. Sustained cellular immune responses to *Borrelia burgdorferi*: lack of correlation with clinical presentation and serology. *Clin Diagn Lab Immunol* 1994; **1**: 373-8.
- 255 Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. *N Engl J Med* 1994; **330**: 229-34.
- 256 Persing DH, Rutledge BJ, Rys PN, et al. Target imbalance: disparity of *Borrelia burgdorferi* genetic material in synovial fluid from Lyme arthritis patients. *J Infect Dis* 1994; **169**: 668-72.
- 257 van Dam AP. Molecular diagnosis of *Borrelia* bacteria for the diagnosis of Lyme disease. *Expert Opinion on Medical Diagnostics* 2011; **5**: 1-15.
- 258 Nocton JJ, Bloom BJ, Rutledge BJ, et al. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. *J Infect Dis* 1996; **174**: 623-7.

-
- 259 Gooskens J, Templeton KE, Claas EC, et al. Evaluation of an internally controlled real-time PCR targeting the ospA gene for detection of *Borrelia burgdorferi* sensu lato DNA in cerebrospinal fluid. *Clin Microbiol Infect* 2006; **12**: 894-900.
- 260 Lebech AM, Hindersson P, Vuust J, et al. Comparison of in vitro culture and polymerase chain reaction for detection of *Borrelia burgdorferi* in tissue from experimentally infected animals. *J Clin Microbiol* 1991; **29**: 731-7.
- 261 Eiffert H, Karsten A, Thomssen R, et al. Characterization of *Borrelia burgdorferi* strains in Lyme arthritis. *Scand J Infect Dis* 1998; **30**: 265-8.
- 262 Jaulhac B, Chary-Valckenaere I, Sibilia J, et al. Detection of *Borrelia burgdorferi* by DNA amplification in synovial tissue samples from patients with Lyme arthritis. *Arthritis Rheum* 1996; **39**: 736-45.
- 263 Liebling MR, Nishio MJ, Rodriguez A, et al. The polymerase chain reaction for the detection of *Borrelia burgdorferi* in human body fluids. *Arthritis Rheum* 1993; **36**: 665-75.
- 264 Priem S, Rittig MG, Kamradt T, et al. An optimized PCR leads to rapid and highly sensitive detection of *Borrelia burgdorferi* in patients with Lyme borreliosis. *J Clin Microbiol* 1997; **35**: 685-90.
- 265 Schnarr S, Putschky N, Jendro MC, et al. Chlamydia and *Borrelia* DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. *Arthritis Rheum* 2001; **44**: 2679-85.
- 266 Bradley JF, Johnson RC, Goodman JL. The persistence of spirochetal nucleic acids in active Lyme arthritis. *Ann Intern Med* 1994; **120**: 487-9.
- 267 Priem S, Burmester GR, Kamradt T, et al. Detection of *Borrelia burgdorferi* by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. *Ann Rheum Dis* 1998; **57**: 118-21.
- 268 Li X, McHugh G, Damle N, et al. Burden and viability of *Borrelia burgdorferi* in skin or joints, of patients with erythema migrans or lyme arthritis. *Arthritis Rheum* 2011.
- 269 Picha D, Moravcova L, Holeckova D, et al. Examination of specific DNA by PCR in patients with different forms of Lyme borreliosis. *Int J Dermatol* 2008; **47**: 1004-10.
- 270 Brettschneider S, Bruckbauer H, Klugbauer N, et al. Diagnostic value of PCR for detection of *Borrelia burgdorferi* in skin biopsy and urine samples from patients with skin borreliosis. *J Clin Microbiol* 1998; **36**: 2658-65.
- 271 Rauter C, Mueller M, Diterich I, et al. Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosis. *Clin Diagn Lab Immunol* 2005; **12**: 910-7.
- 272 Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. *Arthritis Rheum* 2006; **54**: 3079-86.
- 273 Lencakova D, Fingerle V, Stefancikova A, et al. Evaluation of recombinant line immunoblot for detection of Lyme disease in Slovakia: comparison with two other immunoassays. *Vector Borne Zoonotic Dis* 2008; **8**: 381-90.
- 274 Wilske B, Hauser U, Lehnert G, et al. Genospecies and their influence on immunoblot results. *Wien Klin Wochenschr* 1998; **110**: 882-5.
- 275 Stevenson B, von LK, Riley SP, et al. Evolving models of Lyme disease spirochete gene regulation. *Wien Klin Wochenschr* 2006; **118**: 643-52.
- 276 Schwan TG, Burgdorfer W, Garon CF. Changes in infectivity and plasmid profile of the Lyme disease spirochete, *Borrelia burgdorferi*, as a result of in vitro cultivation. *Infect Immun* 1988; **56**: 1831-6.
- 277 Wilske B. Microbiological diagnosis in Lyme borreliosis. *Int J Med Microbiol* 2002; **291 Suppl 33**: 114-9.
- 278 Bunikis J, Barbour AG. Laboratory testing for suspected Lyme disease. *Med Clin North Am* 2002; **86**: 311-40.
- 279 Marangoni A, Sparacino M, Mondardini V, et al. Comparative evaluation of two enzyme linked immunosorbent assay methods and three Western Blot methods for the diagnosis of culture-confirmed early Lyme borreliosis in Italy. *New Microbiol* 2005; **28**: 37-43.
- 280 Magnarelli LA, Anderson JF, Johnson RC, et al. Comparison of different strains of *Borrelia burgdorferi* sensu lato used as antigens in enzyme-linked immunosorbent assays. *J Clin Microbiol* 1994; **32**: 1154-8.
- 281 Smismans A, Goossens VJ, Nulens E, et al. Comparison of five different immunoassays for the detection of *Borrelia burgdorferi* IgM and IgG antibodies. *Clin Microbiol Infect* 2006; **12**: 648-55.

-
- 282 Magnarelli LA, Lawrenz M, Norris SJ, et al. Comparative reactivity of human sera to recombinant VlsE and other *Borrelia burgdorferi* antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis. *J Med Microbiol* 2002; **51**: 649-55.
- 283 Hunfeld KP, Ernst M, Zachary P, et al. Development and laboratory evaluation of a new recombinant ELISA for the serodiagnosis of Lyme disease. *Wien Klin Wochenschr* 2002; **114**: 580-5.
- 284 Fung BP, McHugh GL, Leong JM, et al. Humoral immune response to outer surface protein C of *Borrelia burgdorferi* in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection. *Infect Immun* 1994; **62**: 3213-21.
- 285 Panelius J, Lahdenne P, Saxen H, et al. Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide. *J Neurol* 2003; **250**: 1318-27.
- 286 Wilske B, Preac-Mursic V, Jauris S, et al. Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of *Borrelia burgdorferi*. *Infect Immun* 1993; **61**: 2182-91.
- 287 Hansen K, Asbrink E. Serodiagnosis of erythema migrans and acrodermatitis chronica atrophicans by the *Borrelia burgdorferi* flagellum enzyme-linked immunosorbent assay. *J Clin Microbiol* 1989; **27**: 545-51.
- 288 Marangoni A, Moroni A, Accardo S, et al. *Borrelia burgdorferi* VlsE antigen for the serological diagnosis of Lyme borreliosis. *Eur J Clin Microbiol Infect Dis* 2008; **27**: 349-54.
- 289 Jansson C, Carlsson SA, Granlund H, et al. Analysis of *Borrelia burgdorferi* IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. *Clin Microbiol Infect* 2005; **11**: 147-50.
- 290 Heikkila T, Huppertz HI, Seppala I, et al. Recombinant or peptide antigens in the serology of Lyme arthritis in children. *J Infect Dis* 2003; **187**: 1888-94.
- 291 Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of *Borrelia burgdorferi* compared with 2-tiered testing using whole-cell lysates. *J Infect Dis* 2003; **187**: 1187-99.
- 292 Hansen K, Hindersson P, Pedersen NS. Measurement of antibodies to the *Borrelia burgdorferi* flagellum improves serodiagnosis in Lyme disease. *J Clin Microbiol* 1988; **26**: 338-46.
- 293 Porwancher R. Improving the specificity of recombinant immunoassays for Lyme disease. *J Clin Microbiol* 2003; **41**: 2791.
- 294 Hauser U, Lehnert G, Wilske B. Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. *J Clin Microbiol* 1999; **37**: 2241-7.
- 295 Kaiser R. False-negative serology in patients with neuroborreliosis and the value of employing of different borrelial strains in serological assays. *J Med Microbiol* 2000; **49**: 911-5.
- 296 Dressler F, Whalen JA, Reinhardt BN, et al. Western blotting in the serodiagnosis of Lyme disease. *J Infect Dis* 1993; **167**: 392-400.
- 297 Hunfeld KP, Stanek G, Straube E, et al. Quality of Lyme disease serology. Lessons from the German Proficiency Testing Program 1999-2001. A preliminary report. *Wien Klin Wochenschr* 2002; **114**: 591-600.
- 298 Tilton RC, Sand MN, Manak M. The western immunoblot for Lyme disease: determination of sensitivity, specificity, and interpretive criteria with use of commercially available performance panels. *Clin Infect Dis* 1997; **25 Suppl 1**: S31-S34.
- 299 Engstrom SM, Shoop E, Johnson RC. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. *J Clin Microbiol* 1995; **33**: 419-27.
- 300 Qureshi MZ, New D, Zulqarni NJ, et al. Overdiagnosis and overtreatment of Lyme disease in children. *Pediatr Infect Dis J* 2002; **21**: 12-4.
- 301 Porwancher R. A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. *J Infect Dis* 1999; **179**: 1021-4.
- 302 Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, et al. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. *Clin Infect Dis* 2010; **50**: 20-6.
- 303 Robertson J, Guy E, Andrews N, et al. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. *J Clin Microbiol* 2000; **38**: 2097-102.
- 304 Dressler F, Ackermann R, Steere AC. Antibody responses to the three genomic groups of *Borrelia burgdorferi* in European Lyme borreliosis. *J Infect Dis* 1994; **169**: 313-8.

-
- 305 Roessler D, Hauser U, Wilske B. Heterogeneity of BmpA (P39) among European isolates of *Borrelia burgdorferi sensu lato* and influence of interspecies variability on serodiagnosis. *J Clin Microbiol* 1997; **35**: 2752-8.
- 306 Goettner G, Schulte-Spechtel U, Hillermann R, et al. Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. *J Clin Microbiol* 2005; **43**: 3602-9.
- 307 Mogilyansky E, Loa CC, Adelson ME, et al. Comparison of Western immunoblotting and the C6 Lyme antibody test for laboratory detection of Lyme disease. *Clin Diagn Lab Immunol* 2004; **11**: 924-9.
- 308 Schulte-Spechtel U, Fingerle V, Goettner G, et al. Molecular analysis of decorin-binding protein A (DbpA) reveals five major groups among European *Borrelia burgdorferi sensu lato* strains with impact for the development of serological assays and indicates lateral gene transfer of the dbpA gene. *Int J Med Microbiol* 2006; **296 Suppl 40**: 250-66.
- 309 Johnson BJ, Robbins KE, Bailey RE, et al. Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. *J Infect Dis* 1996; **174**: 346-53.
- 310 Wormser GP, Liveris D, Hanincova K, et al. Effect of *Borrelia burgdorferi* genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. *Clin Infect Dis* 2008; **47**: 910-4.
- 311 Wilske B, Habermann C, Fingerle V, et al. An improved recombinant IgG immunoblot for serodiagnosis of Lyme borreliosis. *Med Microbiol Immunol* 1999; **188**: 139-44.
- 312 Nowakowski J, Schwartz I, Liveris D, et al. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. *Clin Infect Dis* 2001; **33**: 2023-7.
- 313 Wormser GP, Schriefer M, Aguero-Rosenfeld ME, et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. *Diagn Microbiol Infect Dis* 2013; **75**: 9-15.
- 314 Peltomaa M, McHugh G, Steere AC. The VlsE (IR6) peptide ELISA in the serodiagnosis of Lyme facial paralysis. *Otol Neurotol* 2004; **25**: 838-41.
- 315 Branda JA, Linskey K, Kim YA, et al. Two-Tiered Antibody Testing for Lyme Disease With Use of 2 Enzyme Immunoassays, a Whole-Cell Sonicate Enzyme Immunoassay Followed by a VlsE C6 Peptide Enzyme Immunoassay. *Clin Infect Dis* 2011; **53**: 541-7.
- 316 Nyman D, Willen L, Jansson C, et al. VlsE C6 peptide and IgG ELISA antibody analysis for clinical diagnosis of Lyme borreliosis in an endemic area. *Clin Microbiol Infect* 2006; **12**: 496-7.
- 317 Aguero-Rosenfeld ME, Nowakowski J, Bittker S, et al. Evolution of the serologic response to *Borrelia burgdorferi* in treated patients with culture-confirmed erythema migrans. *J Clin Microbiol* 1996; **34**: 1-9.
- 318 Karlsson M, Mollegard I, Stiernstedt G, et al. Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis. *Eur J Clin Microbiol Infect Dis* 1989; **8**: 871-7.
- 319 Hristea A, Hristescu S, Ciufecuc C, et al. Seroprevalence of *Borrelia burgdorferi* in Romania. *Eur J Epidemiol* 2001; **17**: 891-6.
- 320 Cinco M, Barbone F, Grazia CM, et al. Seroprevalence of tick-borne infections in forestry rangers from northeastern Italy. *Clin Microbiol Infect* 2004; **10**: 1056-61.
- 321 Oteiza-Olaso J, Tiberio-Lopez G, Martinez dA, V, et al. [Seroprevalence of Lyme disease in Navarra, Spain]. *Med Clin (Barc)* 2011; **136**: 336-9.
- 322 Kuiper H, de Jongh BM, Nauta AP, et al. Lyme borreliosis in Dutch forestry workers. *J Infect* 1991; **23**: 279-86.
- 323 Rojko T, Ruzic-Sabljić E, Strle F, et al. Prevalence and incidence of Lyme borreliosis among Slovene forestry workers during the period of tick activity. *Wien Klin Wochenschr* 2005; **117**: 219-25.
- 324 Kaya AD, Parlak AH, Ozturk CE, et al. Seroprevalence of *Borrelia burgdorferi* infection among forestry workers and farmers in Duzce, north-western Turkey. *New Microbiol* 2008; **31**: 203-9.
- 325 Berglund J, Eitrem R, Norrby SR. Long-term study of Lyme borreliosis in a highly endemic area in Sweden. *Scand J Infect Dis* 1996; **28**: 473-8.
- 326 Kalish RA, McHugh G, Granquist J, et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to *Borrelia burgdorferi* 10-20 years after active Lyme disease. *Clin Infect Dis* 2001; **33**: 780-5.
- 327 Treib J, Fernandez A, Haass A, et al. Clinical and serologic follow-up in patients with neuroborreliosis. *Neurology* 1998; **51**: 1489-91.

-
- 328 Hilton E, Tramontano A, DeVoti J, et al. Temporal study of immunoglobulin M seroreactivity to *Borrelia burgdorferi* in patients treated for Lyme borreliosis. *J Clin Microbiol* 1997; **35**: 774-6.
- 329 Hammers-Berggren S, Lebech AM, Karlsson M, et al. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. *J Clin Microbiol* 1994; **32**: 1519-25.
- 330 Lomholt H, Lebech AM, Hansen K, et al. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. *Acta Derm Venereol* 2000; **80**: 362-6.
- 331 Mullegger RR, Glatz M. Is serological follow-up useful for patients with cutaneous Lyme borreliosis? *Curr Probl Dermatol* 2009; **37**: 178-82.
- 332 Glatz M, Fingerle V, Wilske B, et al. Immunoblot analysis of the seroreactivity to recombinant *Borrelia burgdorferi* sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans. *Dermatology* 2008; **216**: 93-103.
- 333 Hammers-Berggren S, Lebech AM, Karlsson M, et al. Serological follow-up after treatment of *Borrelia* arthritis and acrodermatitis chronica atrophicans. *Scand J Infect Dis* 1994; **26**: 339-47.
- 334 Kannian P, McHugh G, Johnson BJ, et al. Antibody responses to *Borrelia burgdorferi* in patients with antibiotic-refractory, antibiotic-responsive, or non-antibiotic-treated Lyme arthritis. *Arthritis Rheum* 2007; **56**: 4216-25.
- 335 Wang D, Botkin DJ, Norris SJ. Characterization of the vls antigenic variation loci of the Lyme disease spirochaetes *Borrelia garinii* Ip90 and *Borrelia afzelii* ACAI. *Mol Microbiol* 2003; **47**: 1407-17.
- 336 Kawabata H, Myouga F, Inagaki Y, et al. Genetic and immunological analyses of Vls (VMP-like sequences) of *Borrelia burgdorferi*. *Microb Pathog* 1998; **24**: 155-66.
- 337 Deitsch KW, Lukehart SA, Stringer JR. Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. *Nat Rev Microbiol* 2009; **7**: 493-503.
- 338 Liang FT, Philipp MT. Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of *Borrelia burgdorferi*. *Infect Immun* 1999; **67**: 6702-6.
- 339 Liang FT, Steere AC, Marques AR, et al. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of *Borrelia burgdorferi* vlsE. *J Clin Microbiol* 1999; **37**: 3990-6.
- 340 Liang FT, Aberer E, Cinco M, et al. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of *Borrelia burgdorferi* SL. *J Infect Dis* 2000; **182**: 1455-62.
- 341 Liang FT, Alvarez AL, Gu Y, et al. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of *Borrelia burgdorferi*. *J Immunol* 1999; **163**: 5566-73.
- 342 Embers ME, Jacobs MB, Johnson BJ, et al. Dominant epitopes of the C6 diagnostic peptide of *Borrelia burgdorferi* are largely inaccessible to antibody on the parent VlsE molecule. *Clin Vaccine Immunol* 2007; **14**: 931-6.
- 343 Liang FT, Bowers LC, Philipp MT. C-terminal invariable domain of VlsE is immunodominant but its antigenicity is scarcely conserved among strains of Lyme disease spirochetes. *Infect Immun* 2001; **69**: 3224-31.
- 344 Gottner G, Schulte-Spechtel U, Wilske B. Heterogeneity of the immunodominant surface protein VlsE among the three genospecies of *Borrelia burgdorferi* pathogenic for humans. *Int J Med Microbiol* 2004; **293 Suppl 37**: 172-3.
- 345 Sillanpaa H, Lahdenne P, Sarvas H, et al. Immune responses to borrelial VlsE IR6 peptide variants. *Int J Med Microbiol* 2007; **297**: 45-52.
- 346 Embers ME, Wormser GP, Schwartz I, et al. *Borrelia burgdorferi* spirochetes that harbor only a portion of the lp28-1 plasmid elicit antibody responses that are detectable with the C6 Lyme test. *Clin Vaccine Immunol* 2006; .
- 347 Philipp MT, Bowers LC, Fawcett PT, et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of *Borrelia burgdorferi* infection in experimental animals and in humans. *J Infect Dis* 2001; **184**: 870-8.
- 348 Philipp MT, Wormser GP, Marques AR, et al. A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. *Clin Diagn Lab Immunol* 2005; **12**: 1069-74.
- 349 Marangoni A, Sambri V, Accardo S, et al. A decrease in the immunoglobulin G antibody response against the VlsE protein of *Borrelia burgdorferi* sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. *Clin Vaccine Immunol* 2006; **13**: 525-9.

-
- 350 Philipp MT, Marques AR, Fawcett PT, et al. C6 test as an indicator of therapy outcome for patients with localized or disseminated Lyme borreliosis. *J Clin Microbiol* 2003; **41**: 4955-60.
- 351 Peltomaa M, McHugh G, Steere AC. Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of *Borrelia burgdorferi* after successful antibiotic treatment of Lyme disease. *J Infect Dis* 2003; **187**: 1178-86.
- 352 Fleming RV, Marques AR, Klemmner MS, et al. Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. *Eur J Clin Microbiol Infect Dis* 2004; **23**: 615-8.
- 353 Martin R, Martens U, Sticht-Groh V, et al. Persistent intrathecal secretion of oligoclonal, *Borrelia burgdorferi*-specific IgG in chronic meningoradiculomyelitis. *J Neurol* 1988; **235**: 229-33.
- 354 Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. *Neurology* 1995; **45**: 1663-70.
- 355 Hansen K, Cruz M, Link H. Oligoclonal *Borrelia burgdorferi*-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. *J Infect Dis* 1990; **161**: 1194-202.
- 356 Blanc F, Jaulhac B, Fleury M, et al. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. *Neurology* 2007; **69**: 953-8.
- 357 Henningsson AJ, Malmvall BE, Ernerudh J, et al. Neuroborreliosis - an epidemiological, clinical and health economical study from an endemic area in the south-east of Sweden. *Clin Microbiol Infect* 2010; **16**: 1245-51.
- 358 Halperin JJ. Facial nerve palsy associated with Lyme disease. *Muscle Nerve* 2003; **28**: 516-7.
- 359 Steere AC, Berardi VP, Weeks KE, et al. Evaluation of the intrathecal antibody response to *Borrelia burgdorferi* as a diagnostic test for Lyme neuroborreliosis. *J Infect Dis* 1990; **161**: 1203-9.
- 360 Skarpaas T, Ljostad U, Sobyte M, et al. Sensitivity and specificity of a commercial C6 peptide enzyme immuno assay in diagnosis of acute Lyme neuroborreliosis. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 675-7.
- 361 Skogman BH, Croner S, Forsberg P, et al. Improved laboratory diagnostics of Lyme neuroborreliosis in children by detection of antibodies to new antigens in cerebrospinal fluid. *Pediatr Infect Dis J* 2008; **27**: 605-12.
- 362 Vermeersch P, Ressler S, Nackers E, et al. The C6 Lyme antibody test has low sensitivity for antibody detection in cerebrospinal fluid. *Diagn Microbiol Infect Dis* 2009; **64**: 347-9.
- 363 Wilske B. Epidemiology and diagnosis of Lyme borreliosis. *Ann Med* 2005; **37**: 568-79.
- 364 Kaiser R, Lucking CH. Intrathecal synthesis of specific antibodies in neuroborreliosis. Comparison of different ELISA techniques and calculation methods. *J Neurol Sci* 1993; **118**: 64-72.
- 365 Kaiser R, Rasiyah C, Gassmann G, et al. Intrathecal antibody synthesis in Lyme neuroborreliosis: use of recombinant p41 and a 14-kDa flagellin fragment in ELISA. *J Med Microbiol* 1993; **39**: 290-7.
- 366 Hansen K, Lebech AM. Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of *Borrelia burgdorferi*-specific immunoglobulin G, A, and M. *Ann Neurol* 1991; **30**: 197-205.
- 367 Hartmann M, Pfdenhauer K. Intrathecal antibody production against *Borrelia burgdorferi* in a patient with relapsing-remitting multiple sclerosis. *Eur J Neurol* 2003; **10**: 747-8.
- 368 Ljostad U, Skarpaas T, Myglund A. Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. *Eur J Neurol* 2007; **14**: 873-6.
- 369 Albisetti M, Schaer G, Good M, et al. Diagnostic value of cerebrospinal fluid examination in children with peripheral facial palsy and suspected Lyme borreliosis. *Neurology* 1997; **49**: 817-24.
- 370 Bennet R, Lindgren V, Zweyberg WB. *Borrelia* antibodies in children evaluated for Lyme neuroborreliosis. *Infection* 2008; **36**: 463-6.
- 371 Stiernstedt GT, Granstrom M, Hederstedt B, et al. Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. *J Clin Microbiol* 1985; **21**: 819-25.
- 372 Tjernberg I, Henningsson AJ, Eliasson I, et al. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. *J Infect* 2011; **62**: 149-58.
- 373 Pierer K, Stunzner D, Feichtinger M, et al. Is IgM of diagnostic value in case of delayed intrathecal production of IgG antibodies? *Wien Klin Wochenschr* 1999; **111**: 957-60.
- 374 Hammers-Berggren S, Hansen K, Lebech AM, et al. *Borrelia burgdorferi*-specific intrathecal antibody production in neuroborreliosis: a follow-up study. *Neurology* 1993; **43**: 169-75.

- 375 Kruger H, Reuss K, Pulz M, et al. Meningoradiculitis and encephalomyelitis due to *Borrelia burgdorferi*: a follow-up study of 72 patients over 27 years. *J Neurol* 1989; **236**: 322-8.
- 376 Roux F, Boyer E, Jaulhac B, et al. Lyme meningoradiculitis: prospective evaluation of biological diagnosis methods. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 685-93.
- 377 Chang BL, Shih CM, Ro LS, et al. Acute neuroborreliosis with involvement of the central nervous system. *J Neurol Sci* 2010; **295**: 10-5.
- 378 Wilske B, Schierz G, Preac-Mursic V, et al. Intrathecal production of specific antibodies against *Borrelia burgdorferi* in patients with lymphocytic meningoradiculitis (Bannwarth's syndrome). *J Infect Dis* 1986; **153**: 304-14.
- 379 Rupprecht TA, Kirschning CJ, Popp B, et al. *Borrelia garinii* induces CXCL13 production in human monocytes through Toll-like receptor 2. *Infect Immun* 2007; **75**: 4351-6.
- 380 Rupprecht TA, Pfister HW, Angele B, et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. *Neurology* 2005; **65**: 448-50.
- 381 Ljostad U, Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. *J Neurol* 2008; **255**: 732-7.
- 382 Senel M, Rupprecht TA, Tumani H, et al. The chemokine CXCL13 in acute neuroborreliosis. *J Neurol Neurosurg Psychiatry* 2010; **81**: 929-33.
- 383 Schmidt C, Plate A, Angele B, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. *Neurology* 2011; **76**: 1051-8.
- 384 Widney DP, Breen EC, Boscardin WJ, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. *J Interferon Cytokine Res* 2005; **25**: 702-6.
- 385 Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. *Neurology* 2009; **73**: 2003-10.
- 386 Schiffer L, Kumpers P, Davalos-Misslitz AM, et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). *Nephrol Dial Transplant* 2009; **24**: 3708-12.
- 387 Lee HT, Shiao YM, Wu TH, et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. *J Rheumatol* 2010; **37**: 45-52.
- 388 Schiffer L, Kielstein JT, Haubitz M, et al. Elevation of serum CXCL13 in SLE as well as in sepsis. *Lupus* 2010.
- 389 Mullegger RR, Means TK, Shin JJ, et al. Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. *Infect Immun* 2007; **75**: 4621-8.
- 390 Wutte N, Berghold A, Krainberger I, et al. Serum CXCL13 Chemokine is Not a Marker for Active Lyme Borreliosis. *Acta Derm Venereol* 2011.
- 391 Kraiczy P, Weigand J, Wichelhaus TA, et al. In vitro activities of fluoroquinolones against the spirochete *Borrelia burgdorferi*. *Antimicrob Agents Chemother* 2001; **45**: 2486-94.
- 392 Hunfeld KP, Weigand J, Wichelhaus TA, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against *Borrelia burgdorferi*. *Int J Antimicrob Agents* 2001; **17**: 203-8.
- 393 Hunfeld KP, Kraiczy P, Kekoukh E, et al. Standardised in vitro susceptibility testing of *Borrelia burgdorferi* against well-known and newly developed antimicrobial agents—possible implications for new therapeutic approaches to Lyme disease. *Int J Med Microbiol* 2002; **291 Suppl 33**: 125-37.
- 394 Hunfeld KP, Rodel R, Wichelhaus TA. In vitro activity of eight oral cephalosporins against *Borrelia burgdorferi*. *Int J Antimicrob Agents* 2003; **21**: 313-8.
- 395 Hunfeld KP, Wichelhaus TA, Rodel R, et al. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete *Borrelia burgdorferi*. *Antimicrob Agents Chemother* 2004; **48**: 344-7.
- 396 Hunfeld KP, Brade V. Antimicrobial susceptibility of *Borrelia burgdorferi* sensu lato: what we know, what we don't know, and what we need to know. *Wien Klin Wochenschr* 2006; **118**: 659-68.
- 397 Hunfeld KP, Kraiczy P, Wichelhaus TA, et al. New colorimetric microdilution method for in vitro susceptibility testing of *Borrelia burgdorferi* against antimicrobial substances. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 27-32.
- 398 Lakos A, Nagy G. [Effect of an antibiotic combination on the propagation of *Borrelia burgdorferi*, causative agent of Lyme disease]. *Orv Hetil* 1999; **140**: 1529-32.

-
- 399 Johnson RC. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. *Rev Infect Dis* 1989; **11 Suppl 6**: S1505-S1510.
- 400 Dever LL, Jorgensen JH, Barbour AG. In vitro activity of vancomycin against the spirochete *Borrelia burgdorferi*. *Antimicrob Agents Chemother* 1993; **37**: 1115-21.
- 401 Barthold SW, Hodzic E, Imai DM, et al. Ineffectiveness of tigecycline against persistent *Borrelia burgdorferi*. *Antimicrob Agents Chemother* 2010; **54**: 643-51.
- 402 Yang X, Nguyen A, Qiu D, et al. In vitro activity of tigecycline against multiple strains of *Borrelia burgdorferi*. *J Antimicrob Chemother* 2009; **63**: 709-12.
- 403 Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against *Borrelia burgdorferi*: a comparison of results for the three genospecies *Borrelia afzelii*, *Borrelia garinii*, and *Borrelia burgdorferi sensu stricto*. *J Clin Microbiol* 2003; **41**: 1791-3.
- 404 Hansen K, Hovmark A, Lebech AM, et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. *Acta Derm Venereol* 1992; **72**: 297-300.
- 405 Barsic B, Maretic T, Majerus L, et al. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. *Infection* 2000; **28**: 153-6.
- 406 Strle F, Maraspin V, Lotric-Furlan S, et al. Azithromycin and doxycycline for treatment of *Borrelia* culture-positive erythema migrans. *Infection* 1996; **24**: 64-8.
- 407 Strle F, Preac-Mursic V, Cimperman J, et al. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. *Infection* 1993; **21**: 83-8.
- 408 Weber K, Wilske B, Preac-Mursic V, et al. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. *Infection* 1993; **21**: 367-72.
- 409 Dattwyler RJ, Halperin JJ, Volkman DJ, et al. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. *Lancet* 1988; **1**: 1191-4.
- 410 Pfister HW, Preac-Mursic V, Wilske B, et al. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. *Arch Neurol* 1989; **46**: 1190-4.
- 411 Hassler D, Zoller L, Haude M, et al. Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study. *Infection* 1990; **18**: 16-20.
- 412 Ljostad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicenter, non-inferiority, double-blind, randomised trial. *Lancet Neurol* 2008; **7**: 690-5.
- 413 Hunfeld KP, Ruzic-Sabljic E, Norris DE, et al. Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance. *Int J Med Microbiol* 2006; **296 Suppl 40**: 233-41.
- 414 Mygland A, Ljostad U, Fingerle V, et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur J Neurol* 2010; **17**: 8-4.
- 415 EUCALB guideline. In: 2009
- 416 Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006; **43**: 1089-134.
- 417 Dutch Guideline Lyme Borreliosis, CBO Richtlijn Lyme Borreliose. In: 2004
- 418 Wormser GP, O'Connell S. Treatment of infection caused by *Borrelia burgdorferi sensu lato*. *Expert Rev Anti Infect Ther* 2011; **9**: 245-60.
- 419 Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2007; **69**: 91-102.
- 420 Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2003; **138**: 697-704.
- 421 Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med* 1997; **337**: 289-94.
- 422 Weber K, Preac-Mursic V, Neubert U, et al. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. *Ann N Y Acad Sci* 1988; **539**: 324-45.
- 423 Aberer E, Breier F, Stanek G, et al. Success and failure in the treatment of acrodermatitis chronica atrophicans. *Infection* 1996; **24**: 85-7.
- 424 Bentas W, Karch H, Huppertz HI. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. *J Rheumatol* 2000; **27**: 2025-30.

- 425 Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. *Arthritis Rheum* 1994; **37**: 878-88.
- 426 Caperton EM, Heim-Duthoy KL, Matzke GR, et al. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. *Arch Intern Med* 1990; **150**: 1677-82.
- 427 Steere AC, Green J, Schoen RT, et al. Successful parenteral penicillin therapy of established Lyme arthritis. *N Engl J Med* 1985; **312**: 869-74.
- 428 Carlson D, Hernandez J, Bloom BJ, et al. Lack of *Borrelia burgdorferi* DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. *Arthritis Rheum* 1999; **42**: 2705-9.
- 429 Steere AC. Diagnosis and treatment of Lyme arthritis. *Med Clin North Am* 1997; **81**: 179-94.
- 430 Steere AC, Glickstein L. Elucidation of Lyme arthritis. *Nat Rev Immunol* 2004; **4**: 143-52.
- 431 Pfister HW, Preac-Mursic V, Wilske B, et al. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. *J Infect Dis* 1991; **163**: 311-8.
- 432 Skoldenberg B, Stiernstedt G, Karlsson M, et al. Treatment of Lyme borreliosis with emphasis on neurological disease. *Ann N Y Acad Sci* 1988; **539**: 317-23.
- 433 Mullegger RR, Millner MM, Stanek G, et al. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children—a prospective study. *Infection* 1991; **19**: 279-83.
- 434 Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. *J Neurol* 1989; **236**: 464-9.
- 435 Kowalski TJ, Berth WL, Mathiason MA, et al. Oral antibiotic treatment and long-term outcomes of Lyme facial nerve palsy. *Infection* 2011.
- 436 Clark JR, Carlson RD, Sasaki CT, et al. Facial paralysis in Lyme disease. *Laryngoscope* 1985; **95**: 1341-5.
- 437 Kalish RA, Kaplan RF, Taylor E, et al. Evaluation of study patients with Lyme disease, 10-20-year follow-up. *J Infect Dis* 2001; **183**: 453-60.
- 438 Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001; **56**: 830-6.
- 439 Salinas RA, Alvarez G, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial paralysis). *Cochrane Database Syst Rev* 2004: CD001942.
- 440 Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. *N Engl J Med* 2007; **357**: 1598-607.
- 441 Goudakos JK, Markou KD. Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bell palsy: a systematic review and meta-analysis. *Arch Otolaryngol Head Neck Surg* 2009; **135**: 558-64.
- 442 Pfister HW, Einhaupl K, Franz P, et al. Corticosteroids for Radicular Pain in Bannwarth's Syndrome. *Annals of the New York Academy of Sciences* 2006; **539**: 485-7.
- 443 Massengo SA, Bonnet F, Braun C, et al. Severe neuroborreliosis: The benefit of prolonged high-dose combination of antimicrobial agents with steroids—an illustrative case. *Diagn Microbiol Infect Dis* 2005; **51**: 127-30.
- 444 Eikeland R, Mygland A, Herlofson K, et al. European neuroborreliosis: quality of life 30 months after treatment. *Acta Neurol Scand* 2011.
- 445 Ljostad U, Mygland A. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. *Eur J Neurol* 2010; **17**: 118-23.
- 446 Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. *J Infect Dis* 1999; **180**: 377-83.
- 447 Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. *N Engl J Med* 1990; **323**: 1438-44.
- 448 McAuliffe P, Brassard MR, Fallon B. Memory and executive functions in adolescents with posttreatment Lyme disease. *Appl Neuropsychol* 2008; **15**: 208-19.
- 449 Ljostad U, Mygland A. The phenomenon of 'chronic Lyme'; an observational study. *Eur J Neurol* 2012; **19**: 1128-35.
- 450 Skogman BH, Croner S, Nordwall M, et al. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. *Pediatr Infect Dis J* 2008; **27**: 1089-94.
- 451 Berglund J, Stjernberg L, Ornstein K, et al. 5-y Follow-up study of patients with neuroborreliosis. *Scand J Infect Dis* 2002; **34**: 421-5.
- 452 Cimperman J, Maraspin V, Lotric-Furlan S, et al. Lyme meningitis: a one-year follow up controlled study. *Wien Klin Wochenschr* 1999; **111**: 961-3.

-
- 453 Seltzer EG, Gerber MA, Cartter ML, et al. Long-term outcomes of persons with Lyme disease. *JAMA* 2000; **283**: 609-16.
- 454 Cerar D, Cerar T, Ruzic-Sabljic E, et al. Subjective symptoms after treatment of early Lyme disease. *Am J Med* 2010; **123**: 79-86.
- 455 Kowalski TJ, Tata S, Berth W, et al. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. *Clin Infect Dis* 2010; **50**: 512-20.
- 456 Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. *Am J Med* 2003; **115**: 91-6.
- 457 Nadelman RB, Hanincova K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. *N Engl J Med* 2012; **367**: 1883-90.
- 458 Hodzic E, Feng S, Holden K, et al. Persistence of *Borrelia burgdorferi* following antibiotic treatment in mice. *Antimicrob Agents Chemother* 2008; **52**: 1728-36.
- 459 Hodzic E, Feng S, Freet KJ, et al. *Borrelia burgdorferi* population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. *Infect Immun* 2003; **71**: 5042-55.
- 460 Bockenstedt LK, Mao J, Hodzic E, et al. Detection of attenuated, noninfectious spirochetes in *Borrelia burgdorferi*-infected mice after antibiotic treatment. *J Infect Dis* 2002; **186**: 1430-7.
- 461 Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology* 2008; **70**: 992-1003.
- 462 Oksi J, Nikoskelainen J, Hiekkänen H, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 571-81.
- 463 Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology* 2003; **60**: 1923-30.
- 464 Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? *Neurology* 2003; **60**: 1916-22.
- 465 Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med* 2001; **345**: 85-92.
- 466 Djukic M, Schmidt-Samoa C, Nau R, et al. The diagnostic spectrum in patients with suspected chronic Lyme neuroborreliosis—the experience from one year of a university hospital's Lyme neuroborreliosis outpatients clinic. *Eur J Neurol* 2011; **18**: 547-55.
- 467 Seidel MF, Domene AB, Vetter H. Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 611-7.
- 468 Holzbauer SM, Kemperman MM, Lynfield R. Death due to community-associated *Clostridium difficile* in a woman receiving prolonged antibiotic therapy for suspected Lyme disease. *Clin Infect Dis* 2010; **51**: 369-70.
- 469 Patel R, Grogg KL, Edwards WD, et al. Death from inappropriate therapy for Lyme disease. *Clin Infect Dis* 2000; **31**: 1107-9.
- 470 Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. *J Infect Dis* 1995; **171**: 356-61.
- 471 Steere AC, Taylor E, McHugh GL, et al. The overdiagnosis of Lyme disease. *JAMA* 1993; **269**: 1812-6.
- 472 Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'. *South Med J* 1991; **84**: 1263-5.
- 473 Schuijt TJ, Hovius JW, van der Poll T, et al. Lyme borreliosis vaccination: the facts, the challenge, the future. *Trends Parasitol* 2011; **27**: 40-7.
- 474 Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. *N Engl J Med* 1998; **339**: 209-15.
- 475 Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? *Clin Infect Dis* 2011; **52 Suppl 3**: s253-s258.
- 476 LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliaecidal antibodies provides a high level of protection against canine Lyme disease. *Clin Vaccine Immunol* 2009; **16**: 253-9.

- 477 Nassal M, Skamel C, Vogel M, et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. *Int J Med Microbiol* 2008; **298**: 135-42.
- 478 LaRocca TJ, Holthausen DJ, Hsieh C, et al. The bactericidal effect of a complement-independent antibody is osmolytic and specific to *Borrelia*. *Proc Natl Acad Sci U S A* 2009; **106**: 10752-7.
- 479 LaRocca TJ, Crowley JT, Cusack BJ, et al. Cholesterol lipids of *Borrelia burgdorferi* form lipid rafts and are required for the bactericidal activity of a complement-independent antibody. *Cell Host Microbe* 2010; **8**: 331-42.
- 480 Hanson MS, Patel NK, Cassatt DR, et al. Evidence for vaccine synergy between *Borrelia burgdorferi* decorin binding protein A and outer surface protein A in the mouse model of Lyme borreliosis. *Infect Immun* 2000; **68**: 6457-60.
- 481 Brown EL, Kim JH, Reisenbichler ES, et al. Multicomponent Lyme vaccine: three is not a crowd. *Vaccine* 2005; **23**: 3687-96.
- 482 Narasimhan S, Deponte K, Marcantonio N, et al. Immunity against *Ixodes scapularis* salivary proteins expressed within 24 hours of attachment thwarts tick feeding and impairs *Borrelia* transmission. *PLoS ONE* 2007; **2**: e451.
- 483 Wikel SK, Ramachandra RN, Bergman DK, et al. Infestation with pathogen-free nymphs of the tick *Ixodes scapularis* induces host resistance to transmission of *Borrelia burgdorferi* by ticks. *Infect Immun* 1997; **65**: 335-8.
- 484 Nazario S, Das S, de Silva AM, et al. Prevention of *Borrelia burgdorferi* transmission in guinea pigs by tick immunity. *Am J Trop Med Hyg* 1998; **58**: 780-5.
- 485 Burke G, Wikel SK, Spielman A, et al. Hypersensitivity to ticks and Lyme disease risk. *Emerg Infect Dis* 2005; **11**: 36-41.
- 486 Bell JF, Stewart SJ, Wikel SK. Resistance to tick-borne *Francisella tularensis* by tick-sensitized rabbits: allergic klendusity. *Am J Trop Med Hyg* 1979; **28**: 876-80.
- 487 Miller NJ, Rainone EE, Dyer MC, et al. Tick bite protection with permethrin-treated summer-weight clothing. *J Med Entomol* 2011; **48**: 327-33.
- 488 Vaughn MF, Meshnick SR. Pilot Study Assessing the Effectiveness of Long-Lasting Permethrin-Impregnated Clothing for the Prevention of Tick Bites. *Vector Borne Zoonotic Dis* 2011.
- 489 Personal protection against biting insects and ticks. *Parasite* 2011; **18**: 93-111.
- 490 Stafford K.C. *Tick management handbook: an integrated guide for homeowners, pest control operators, and public health officials for the prevention of tick-associated disease*. 2004.
- 491 Stafford KC, III, Allan SA. Field applications of entomopathogenic fungi *Beauveria bassiana* and *Metarhizium anisopliae* F52 (Hypocreales: Clavicipitaceae) for the control of *Ixodes scapularis* (Acari: Ixodidae). *J Med Entomol* 2010; **47**: 1107-15.
- 492 Curran KL, Fish D, Piesman J. Reduction of nymphal *Ixodes dammini* (Acari: Ixodidae) in a residential suburban landscape by area application of insecticides. *J Med Entomol* 1993; **30**: 107-13.
- 493 Daniels TJ, Fish D, Falco RC. Evaluation of host-targeted acaricide for reducing risk of Lyme disease in southern New York state. *J Med Entomol* 1991; **28**: 537-43.
- 494 Graf JF, Gogolewski R, Leach-Bing N, et al. Tick control: an industry point of view. *Parasitology* 2004; **129 Suppl**: S427-S442.
- 495 Nachman SA. Prevention of Lyme disease after tick bites. *N Engl J Med* 1993; **328**: 137-9.
- 496 Tjisse-Klasen E, Jacobs JJ, Swart A, et al. Small risk of developing symptomatic tick-borne diseases following a tick bite in the Netherlands. *Parasit Vectors* 2011; **4**: 17.
- 497 Volkman D. Prophylaxis after tick bites. *Lancet Infect Dis* 2007; **7**: 370-1.
- 498 Wormser GP, Dattwyler RJ, Shapiro ED, et al. Single-dose prophylaxis against Lyme disease. *Lancet Infect Dis* 2007; **7**: 371-3.
- 499 Pontrelli L, Dattwyler R, Nachman S. Single-dose doxycycline for the prevention of Lyme disease. *N Engl J Med* 2001; **345**: 1348-50.
- 500 Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N Engl J Med* 2001; **345**: 79-84.
- 501 Stanek G, Strle F. Therapy and prophylaxis in Lyme borreliosis. *Infection* 1996; **24**: 59.
- 502 Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. *Am J Dis Child* 1993; **147**: 945-7.
- 503 Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. *N Engl J Med* 1992; **327**: 1769-73.

-
- 504 Costello CM, Steere AC, Pinkerton RE, et al. A prospective study of tick bites in an endemic area for Lyme disease. *J Infect Dis* 1989; **159**: 136-9.
- 505 Lee J, Wormser GP. Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials. *Int J Antimicrob Agents* 2008; **31**: 235-9.
- 506 Warshafsky S, Lee DH, Francois LK, et al. Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. *J Antimicrob Chemother* 2010; **65**: 1137-44.
- 507 Saint G, I, Gern L, Gray JS, et al. Identification of *Borrelia burgdorferi* sensu lato species in Europe. *Zentralbl Bakteriol* 1998; **287**: 190-5.
- 508 Wilske B, Busch U, Eiffert H, et al. Diversity of OspA and OspC among cerebrospinal fluid isolates of *Borrelia burgdorferi* sensu lato from patients with neuroborreliosis in Germany. *Med Microbiol Immunol* 1996; **184**: 195-201.
- 509 Marconi RT, Hohenberger S, Jauris-Heipke S, et al. Genetic analysis of *Borrelia garinii* OspA serotype 4 strains associated with neuroborreliosis: evidence for extensive genetic homogeneity. *J Clin Microbiol* 1999; **37**: 3965-70.
- 510 Wilske B, Busch U, Fingerle V, et al. Immunological and molecular variability of OspA and OspC. Implications for *Borrelia* vaccine development. *Infection* 1996; **24**: 208-12.
- 511 Wilske B, Preac-Mursic V, Gobel UB, et al. An OspA serotyping system for *Borrelia burgdorferi* based on reactivity with monoclonal antibodies and OspA sequence analysis. *J Clin Microbiol* 1993; **31**: 340-50.
- 512 Margos G, Vollmer SA, Cornet M, et al. MLSA on housekeeping genes defines a new *Borrelia* species. *Appl Environ Microbiol* 2009; **75**: 5410-6.
- 513 Kraiczy P, Skerka C, Kirschfink M, et al. Immune evasion of *Borrelia burgdorferi* by acquisition of human complement regulators FHL-1/reconnectin and Factor H. *Eur J Immunol* 2001; **31**: 1674-84.
- 514 McDowell JV, Harlin ME, Rogers EA, et al. Putative coiled-coil structural elements of the BBA68 protein of Lyme disease spirochetes are required for formation of its factor H binding site. *J Bacteriol* 2005; **187**: 1317-23.
- 515 Kraiczy P, Hellwage J, Skerka C, et al. Immune evasion of *Borrelia burgdorferi*: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. *Eur J Immunol* 2003; **33**: 697-707.
- 516 Prodinge WM, Hellwage J, Spruth M, et al. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. *Biochem J* 1998; **331** (Pt 1): 41-7.
- 517 McDowell JV, Wolfgang J, Tran E, et al. Comprehensive analysis of the factor h binding capabilities of borrelia species associated with lyme disease: delineation of two distinct classes of factor h binding proteins. *Infect Immun* 2003; **71**: 3597-602.
- 518 Kraiczy P, Hanssen-Hubner C, Kitziratschky V, et al. Mutational analyses of the BbCRASP-1 protein of *Borrelia burgdorferi* identify residues relevant for the architecture and binding of host complement regulators FHL-1 and factor H. *Int J Med Microbiol* 2009; **299**: 255-68.
- 519 Cordes FS, Kraiczy P, Roversi P, et al. Structure-function mapping of BbCRASP-1, the key complement factor H and FHL-1 binding protein of *Borrelia burgdorferi*. *Int J Med Microbiol* 2006; **296 Suppl 40**: 177-84.
- 520 Cordes FS, Roversi P, Kraiczy P, et al. A novel fold for the factor H-binding protein BbCRASP-1 of *Borrelia burgdorferi*. *Nat Struct Mol Biol* 2005; **12**: 276-7.
- 521 Kraiczy P, Hunfeld KP, Breiter-Ruddock S, et al. Comparison of two laboratory methods for the determination of serum resistance in *Borrelia burgdorferi* isolates. *Immunobiology* 2000; **201**: 406-19.
- 522 Herzberger P, Siegel C, Skerka C, et al. Human pathogenic *Borrelia spielmanii* sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1. *Infect Immun* 2007; **75**: 4817-25.
- 523 Wang G, van Dam AP, Spanjaard L, et al. Molecular typing of *Borrelia burgdorferi* sensu lato by randomly amplified polymorphic DNA fingerprinting analysis. *J Clin Microbiol* 1998; **36**: 768-76.
- 524 Busch U, Hizo-Teufel C, Boehmer R, et al. Three species of *Borrelia burgdorferi* sensu lato (*B. burgdorferi* sensu stricto, *B. afzelii*, and *B. garinii*) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR. *J Clin Microbiol* 1996; **34**: 1072-8.

-
- 525 Brooks CS, Vuppala SR, Jett AM, et al. Complement regulator-acquiring surface protein 1 imparts resistance to human serum in *Borrelia burgdorferi*. *J Immunol* 2005; **175**: 3299-308.
- 526 Kenedy MR, Vuppala SR, Siegel C, et al. CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in *Borrelia burgdorferi*. *Infect Immun* 2009; **77**: 2773-82.
- 527 Oliver MA, Rojo JM, Rodriguez de CS, et al. Binding of complement regulatory proteins to group A *Streptococcus*. *Vaccine* 2008; **26 Suppl 8**: 175-178.
- 528 Ngampasutadol J, Ram S, Gulati S, et al. Human factor H interacts selectively with *Neisseria gonorrhoeae* and results in species-specific complement evasion. *J Immunol* 2008; **180**: 3426-35.
- 529 Beernink PT, Caugant DA, Welsch JA, et al. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. *J Infect Dis* 2009; **199**: 1360-8.
- 530 Oppermann M, Manuelian T, Jozsi M, et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. *Clin Exp Immunol* 2006; **144**: 342-52.
- 531 Bhide MR, Escudero R, Camafeita E, et al. Complement factor H binding by different Lyme disease and relapsing fever *Borrelia* in animals and human. *BMC Res Notes* 2009; **2**: 134.
- 532 Wang G, van Dam AP, Schwartz I, et al. Molecular typing of *Borrelia burgdorferi* sensu lato: taxonomic, epidemiological, and clinical implications. *Clin Microbiol Rev* 1999; **12**: 633-53.
- 533 Ryffel K, Peter O, Rutti B, et al. Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of *Borrelia burgdorferi* sensu stricto, *B. garinii*, *B. afzelii*, and *B. Valaisiana* in humans. *J Clin Microbiol* 1999; **37**: 4086-92.
- 534 Diza E, Papa A, Vezryi E, et al. *Borrelia valaisiana* in cerebrospinal fluid. *Emerg Infect Dis* 2004; **10**: 1692-3.
- 535 Barthold SW. Specificity of infection-induced immunity among *Borrelia burgdorferi* sensu lato species. *Infect Immun* 1999; **67**: 36-42.
- 536 Barthold SW. Infectivity of *Borrelia burgdorferi* relative to route of inoculation and genotype in laboratory mice. *J Infect Dis* 1991; **163**: 419-20.
- 537 Pachner AR, Dail D, Bai Y, et al. Genotype determines phenotype in experimental Lyme borreliosis. *Ann Neurol* 2004; **56**: 361-70.
- 538 McDowell JV, Hovis KM, Zhang H, et al. Evidence that the BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. *Infect Immun* 2006; **74**: 3030-4.
- 539 von Lackum K, Miller JC, Bykowski T, et al. *Borrelia burgdorferi* regulates expression of complement regulator-acquiring surface protein 1 during the mammal-tick infection cycle. *Infect Immun* 2005; **73**: 7398-405.
- 540 Kraiczy P, Hartmann K, Hellwage J, et al. Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of *Borrelia burgdorferi*. *Int J Med Microbiol* 2004; **293 Suppl 37**: 152-7.
- 541 Brooks CS, Vuppala SR, Jett AM, et al. Complement Regulator-Acquiring Surface Protein 1 Imparts Resistance to Human Serum in *Borrelia burgdorferi*. *J Immunol* 2005; **175**: 3299-308.
- 542 van Burgel ND, Kraiczy P, Schuijt TJ, et al. Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant *Borrelia garinii* OspA serotype 4. *BMC Microbiol* 2010; **10**: 43.
- 543 Bockenstedt LK, Barthold S, Deponte K, et al. *Borrelia burgdorferi* infection and immunity in mice deficient in the fifth component of complement. *Infect Immun* 1993; **61**: 2104-7.
- 544 Circolo A, Garnier G, Fukuda W, et al. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. *Immunopharmacology* 1999; **42**: 135-49.
- 545 Pachner AR, Delaney E, Ricalton NS. Murine Lyme borreliosis: route of inoculation determines immune response and infectivity. *Reg Immunol* 1992; **4**: 345-51.
- 546 Hodzic E, Feng S, Freet KJ, et al. *Borrelia burgdorferi* population kinetics and selected gene expression at the host-vector interface. *Infect Immun* 2002; **70**: 3382-8.
- 547 Barthold SW, Sidman CL, Smith AL. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. *Am J Trop Med Hyg* 1992; **47**: 605-13.

-
- 548 Satoskar AR, Elizondo J, Monteforte GM, et al. Interleukin-4-deficient BALB/c mice develop an enhanced Th1-like response but control cardiac inflammation following *Borrelia burgdorferi* infection. *FEMS Microbiol Lett* 2000; **183**: 319-25.
- 549 Escudero R, Barral M, Perez A, et al. Molecular and pathogenic characterization of *Borrelia burgdorferi* sensu lato isolates from Spain. *J Clin Microbiol* 2000; **38**: 4026-33.
- 550 Kurtenbach K, De Michelis S, Etti S, et al. Host association of *Borrelia burgdorferi* sensu lato--the key role of host complement. *Trends Microbiol* 2002; **10**: 74-9.
- 551 Olsen B, Jaenson TG, Bergstrom S. Prevalence of *Borrelia burgdorferi* sensu lato-infected ticks on migrating birds. *Appl Environ Microbiol* 1995; **61**: 3082-7.
- 552 Kaiser A, Seitz A, Strub O. Prevalence of *Borrelia burgdorferi* sensu lato in the nightingale (*Luscinia megarhynchos*) and other passerine birds. *Int J Med Microbiol* 2002; **291 Suppl 33**: 75-9.
- 553 Gylfe, Olsen B, Strasevicius D, et al. Isolation of Lyme disease *Borrelia* from puffins (*Fratercula arctica*) and seabird ticks (*Ixodes uriae*) on the Faeroe Islands. *J Clin Microbiol* 1999; **37**: 890-6.
- 554 Kurtenbach K, Schafer SM, Sewell HS, et al. Differential survival of Lyme borreliosis spirochetes in ticks that feed on birds. *Infect Immun* 2002; **70**: 5893-5.
- 555 Hanincova K, Schafer SM, Etti S, et al. Association of *Borrelia afzelii* with rodents in Europe. *Parasitology* 2003; **126**: 11-20.
- 556 Barthold SW, de Souza M. Exacerbation of Lyme arthritis in beige mice. *J Infect Dis* 1995; **172**: 778-84.
- 557 Schuijt TJ, Hovius JW, van Burgel ND, et al. The tick salivary protein Salp15 inhibits the killing of serum-sensitive *Borrelia burgdorferi* sensu lato isolates. *Infect Immun* 2008; **76**: 2888-94.
- 558 Hovius JW, van Dam AP, Fikrig E. Tick-host-pathogen interactions in Lyme borreliosis. *Trends Parasitol* 2007; **23**: 434-8.
- 559 Halperin JJ. Nervous system Lyme disease. *Infect Dis Clin North Am* 2008; **22**: 261-74, vi.
- 560 Tjernberg I, Schon T, Ernerudh J, et al. C6-peptide serology as diagnostic tool in neuroborreliosis. *APMIS* 2008; **116**: 393-9.
- 561 Fawcett PT, Rose CD, Gibney KM, et al. Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis. *Clin Diagn Lab Immunol* 1997; **4**: 85-8.
- 562 Picha D, Moravcova L, Zdarsky E, et al. Clinical comparison of immunoblot and antibody index for detection of intrathecal synthesis of specific antibodies in Lyme neuroborreliosis. *Eur J Clin Microbiol Infect Dis* 2000; **19**: 805-6.
- 563 Pachner AR, Dail D, Narayan K, et al. Increased expression of B-lymphocyte chemoattractant, but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic Lyme borreliosis. *Cytokine* 2002; **19**: 297-307.
- 564 Narayan K, Dail D, Li L, et al. The nervous system as ectopic germinal center: CXCL13 and IgG in Lyme neuroborreliosis. *Ann Neurol* 2005; **57**: 813-23.
- 565 Segal BM, Logigian EL. Sublime diagnosis of Lyme neuroborreliosis. *Neurology* 2005; **65**: 351-2.
- 566 Rupprecht TA, Koedel U, Angele B, et al. [Cytokine CXCL13--a possible early CSF marker for neuroborreliosis]. *Nervenarzt* 2006; **77**: 470-3.
- 567 Cagigi A, Mowafi F, Phuong Dang LV, et al. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. *Blood* 2008; **112**: 4401-10.
- 568 Anonymous. NCBI taxonomy database. <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&id=138&lvl=3&lin=f&keep=1&srchmode=1&unlock>.
- 569 Steere AC, Bartenhagen NH, Craft JE, et al. Clinical manifestations of Lyme disease. *Zentralbl Bakteriol Mikrobiol Hyg [A]* 1986; **263**: 201-5.
- 570 Anonymous. Dutch Guideline Lyme Borreliosis, CBO Richtlijn Lyme Borreliose. In: 2012
- 571 Huppertz HI, Bentas W, Haubitze I, et al. Diagnosis of paediatric Lyme arthritis using a clinical score. *Eur J Pediatr* 1998; **157**: 304-8.
- 572 de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? *Rheumatology (Oxford)* 2011; **50**: 93-100.
- 573 Garcia-Monco JC, Frey HM, Villar BF, et al. Lyme disease concurrent with human immunodeficiency virus infection. *Am J Med* 1989; **87**: 325-8.
- 574 Cerny R, Machala L, Bojar M, et al. Neuroborreliosis in an HIV-1 positive patient. *Infection* 2006; **34**: 100-2.

- 575 Dudle G, Opravil M, Luthy R, et al. [Meningitis after acute *Borrelia burgdorferi* infection in HIV infection]. *Dtsch Med Wochenschr* 1997; **122**: 1178-80.
- 576 Cordoliani F, Vignon-Pennamen MD, Assous MV, et al. Atypical Lyme borreliosis in an HIV-infected man. *Br J Dermatol* 1997; **137**: 437-9.
- 577 Raoult D, Hechemy KE, Baranton G. Cross-reaction with *Borrelia burgdorferi* antigen of sera from patients with human immunodeficiency virus infection, syphilis, and leptospirosis. *J Clin Microbiol* 1989; **27**: 2152-5.
- 578 Blatz R, Kuhn HJ, Hermann W, et al. [Neurosyphilis and neuroborreliosis. Retrospective evaluation of 22 cases]. *Nervenarzt* 2005; **76**: 724-32.
- 579 Karp G, Schlaeffer F, Jotkowitz A, et al. Syphilis and HIV co-infection. *Eur J Intern Med* 2009; **20**: 9-13.
- 580 Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. *N Engl J Med* 1997; **337**: 307-14.
- 581 Jones S, Kim T. Fulminant leptospirosis in a patient with human immunodeficiency virus infection: case report and review of the literature. *Clin Infect Dis* 2001; **33**: E31-E33.
- 582 Baradaran-Dilmaghani R, Stanek G. In vitro susceptibility of thirty *Borrelia* strains from various sources against eight antimicrobial chemotherapeutics. *Infection* 1996; **24**: 60-3.
- 583 Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. *Ann Intern Med* 1994; **121**: 560-7.
- 584 Stevenson B, Zuckert WR, Akins DR. Repetition, conservation, and variation: the multiple cp32 plasmids of *Borrelia* species. *J Mol Microbiol Biotechnol* 2000; **2**: 411-22.
- 585 Hanincova K, Taragelova V, Koci J, et al. Association of *Borrelia garinii* and *B. valaisiana* with songbirds in Slovakia. *Appl Environ Microbiol* 2003; **69**: 2825-30.
- 586 Jacobs MB, Norris SJ, Phillippi-Falkenstein KM, et al. Infectivity of the highly transformable *B. burgdorferi*. *Infect Immun* 2006; **74**: 3678-81.
- 587 Lawrenz MB, Kawabata H, Purser JE, et al. Decreased electroporation efficiency in *Borrelia burgdorferi* containing linear plasmids lp25 and lp56: impact on transformation of infectious *B. burgdorferi*. *Infect Immun* 2002; **70**: 4798-804.
- 588 Hernandez M, Pozo L, Gomez I, et al. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection. *Biochem Biophys Res Commun* 2000; **272**: 259-62.
- 589 Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. *FEMS Immunol Med Microbiol* 2007; **49**: 13-21.
- 590 Riesbeck K, Hammas B. Comparison of an automated *Borrelia* indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 517-9.
- 591 Tjernberg I, Kruger G, Eliasson I. C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 37-42.
- 592 Jobe DA, Lovrich SD, Asp KE, et al. Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of *Borrelia burgdorferi* OspC. *Clin Vaccine Immunol* 2008; **15**: 981-5.
- 593 Klutts JS, Ford BA, Perez NR, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. *J Clin Microbiol* 2009; **47**: 3204-10.
- 594 Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. *Sex Transm Dis* 2012; **39**: 291-7.
- 595 Farhi D, Dupin N. Origins of syphilis and management in the immunocompetent patient: facts and controversies. *Clin Dermatol* 2010; **28**: 533-8.
- 596 Nayak S, Acharjya B. VDRL test and its interpretation. *Indian J Dermatol* 2012; **57**: 3-8.
- 597 Mackworth-Young CG, Harris EN, Steere AC, et al. Anticardiolipin antibodies in Lyme disease. *Arthritis Rheum* 1988; **31**: 1052-6.
- 598 Markeljevic J, Sarac H, Rados M. Tremor, seizures and psychosis as presenting symptoms in a patient with chronic lyme neuroborreliosis (LNB). *Coll Antropol* 2011; **35 Suppl 1**: 313-8.
- 599 van Burgel ND, Brandenburg A, Gerritsen HJ, et al. High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients. *Clin Microbiol Infect* 2011; **17**: 1495-500.

-
- 600 Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. *J Neuroinflammation* 2012; **9**: 93.
- 601 Munchhoff P, Wilske B, Preac-Mursic V, et al. Antibodies against *Borrelia burgdorferi* in Bavarian forest workers. *Zentralbl Bakteriol Mikrobiol Hyg A* 1987; **263**: 412-9.
- 602 Kuiper H, van Dam AP, Moll van Charante AW, et al. One year follow-up study to assess the prevalence and incidence of Lyme borreliosis among Dutch forestry workers. *Eur J Clin Microbiol Infect Dis* 1993; **12**: 413-8.
- 603 Ang CW, van Burgel ND. *Borrelia*-serologie in de Nederlandse situatie; interpretatie van testuitslagen. *Nederlands Tijdschrift van Medische Microbiologie* 2012; **20**: 120-5.

List of abbreviations

Ab	Antibodies
ACA	Acrodermatitis Chronica Atroficans
ADEM	Acute disseminated encephalomyelitis
Ag	Antigens
ALS	Amyotrophic lateral sclerosis
AP	Alternative pathway
BD	Healthy Blood Donors
BL	Borrelia lymphocytoma
CFH	Complement factor H
CFHR	Complement factor H related proteins
CMV	Cytomegalo Virus
CNS	Central nervous system
CP	Classical pathway
CRASP	Complement regulatory acquired surface protein
CT	Computed tomography (scan)
EBV	Epstein Barr Virus
EBV-EA	Epstein Barr Virus early antigen
EBV-NA	Epstein Barr Virus nuclear antigen
EBV-VCA	Epstein Barr Virus viral capsid antigen
EEG	Electroencephalogram
EIA	Enzyme immunoassay
ELB	Early Lyme Borreliosis
ELISA	Enzyme-linked immunosorbent assay
EM	Erythema Migrans
FHL-1	Factor H-like protein 1
FNP	Facial Nerve Palsy
HiNHS	Heat inactivated non-immune human serum
HIV	Human immunodeficiency virus 1/2
HSV	Herpes simplex virus
IR	Invariable region
iv	intravenous
LA	Lyme Arthritis
LB	Lyme Borreliosis
LLB	Late Lyme Borreliosis
LNB	Lyme Neuroborreliosis
LP	Lectin pathway
MBC	Minimal Bactericidal Concentration
MBL	Mannose binding lectin
MIC	Minimal inhibitory concentration
MRI	Magnetic resonance imaging
MS	Multiple sclerosis
LNB	Lyme Neuroborreliosis
NHS	Non-immune human serum
NPV	Negative predictive value
PCR	Polymerase chain reaction
PNS	Peripheral nerve system
po	per os
PTLDS	Post treatment Lyme disease syndrome
PPV	Positive predictive value
RF	Reuma factor
SALP	Tick salivary protein
SCR	Short consensus repeats
sl	sensu lato
ss	sensu stricto
ST4	OspA serotype 4
TP	<i>Treponema pallidum</i>
US	United States
VR	Variable region
VZV	Varicella Zoster Virus

